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- Cancer recurrence is attributed to the presence of a tumoral stem 
cell population located in a specific tumoral niche. 
- Cancer treatment should address both cancer stem cells and the 
niche that supports and protects them. 
- Advanced drug delivery systems provide clear benefits for the 
design of therapeutic systems targeted against cancer stem cells 
and their niche. 
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Journal of Pharmaceutics 523 (2017) 490–505. The edited version of the 
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Aldehyde dehydrogenase (ALDH), acute promyelocytic leukemia (APL), all 
trans retinoic acid (ATRA), basic fibroblast growth factor (b-FGF), bone 
morphogenetic protein (BMP),  cancer stem cells (CSC), extracellular matrix 
(ECM), epidermal growth factor receptor (EGFR), Enhanced Permeation and 
Retention (EPR), granulocyte macrophage colony stimulating factor (GM-CSF), 
interferon (IFN), interleukins (IL), hypoxia inducible factor (HIF), N-(2-
hydroxypropyl)methacrylamide (HPMA), lysyl oxidase (LOX), 
lipopolysaccharide (LPS), mesenchymal stem cells (MSCs), poly[α-(4-
aminobutyl)-L-glycolic acid] (PAGA), poly(ε-caprolactone) (PCL), pigment 
epithelium-derived factor (PEDF), poly(ethylene glycol) (PEG), 
polyethyleneimine (PEI), poly-glutamic acid (PGA), poly-lactic acid (PLA), 
poly(lactic-co-glycolic acid) (PLGA), poly(N-methyldietheneamine sebacate) 
(PMDS), polyvinyl pyrrolidone (PVP),  reactive oxygen species (ROS), tumor 
associated-macrophages (TAM), transforming growth factor-beta (TGF-beta), 
toll-like receptor (TLR), tumor initiating cells (TICs), tumor niche (TN), tumor 
necrosis factor-alpha (TNF-α), tyrosine related protein 2 (TRP2), vascular 





Lack of improvement in the treatment options of several types of cancer can 
largely be attributed to the presence of a subpopulation of cancer cells with stem 
cell signatures and to the tumoral niche that supports and protects these cells. 
This review analyses the main strategies that specifically modulate or suppress 
cancer stem cells (CSCs) and the tumoral niche (TN), focusing on the role of 
biomaterials (i.e. implants, nanomedicines, etc.) in these therapies. In the case of 
CSCs, we discuss differentiation therapies and the disruption of critical signaling 
networks. For the TN, we analyze diverse strategies to modulate tumor 
hypervascularization and hypoxia, tumor extracellular matrix, and the 
inflammatory and tumor immunosuppressive environment. Due to their capacity 
to control drug disposition and integrate diverse functionalities, biomaterial-
based therapies can provide important benefits in these strategies. We illustrate 
this by providing case studies where biomaterial-based therapies either show 
CSC suppression and TN disruption or improved delivery of major modulators 
of these features. Finally, we discuss the future of these technologies in the 
framework of these emerging therapeutic concepts. 
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Conventional cancer treatment is based on two premises: first, that cancer cells 
are a homogeneous population that displays a distinct phenotype as compared to 
healthy cells, and that medicines can take advantage of these differences to 
eliminate the disease (Clevers, 2011). The second premise is that the tumoral 
niche is a clinically advantageous feature, at least for nanomedicine-based 
therapies, since its enhances permeability to macromolecules and nanocarriers 
and promotes their accumulation in the tumor (Schätzlein, 2006). Nowadays, 
there is growing evidence demonstrating that these two premises are incorrect or 
at least incomplete. 
Tumor cell heterogeneity is now a widely accepted feature of cancer and can be 
discussed at the genetic and developmental levels, being both of these tightly 
connected. At the genetic level, tumor cells present intrinsic genetic variability, 
which results in several cancer subclones that evolve following Darwinian 
processes in an attempt to adapt towards the environment. This process leads to 
an enrichment of cells presenting advantageous mutations and more aggressive 
phenotype (Greaves and Maley, 2012). At the developmental level, it has been 
confirmed that tumor initiation and relapse is driven by a selected tumor cell 
subpopulation that has high resistance towards conventional therapies and that 
takes advantage of stem cell-specific features (Farrar, 2009)(Marotta and Polyak, 
2009). Antitumorals are designed to target rapidly cycling cells such as those 
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from the tumor bulk, but will spare the quiescent (but deadly) cancer stem cells 
(CSCs) that will generate tumor relapse and metastasis (Clevers, 2011).   
 
Figure 1. General overview of the organization of cancer stem cells (CSCs) and their tumor 
niche (TN). CSCs dwell in complex colonies together with differentiated cancer cells and other 
non-tumoral cell types. The tumoral niche presents several features that are critical for CSC 
physiology and relevant for the design of new therapies. These are: (i) a disorganized and 
hypertrophic vascular niche, (ii) a highly dynamic, remodeled extracellular matrix, (iii) the 
formation of hypoxic regions and (iv) the generation of an inflammatory microenvironment. 
Tumor niche (TN) refers to the microenvironment that interacts with tumor cells 
and regulates their fate. TN has been revealed as a critical barrier for cancer 
treatment and it is analyzed in this manuscript through four different features: 
the vascular niche, the inflammatory and immunosuppresive niche, the hypoxic 
niche and the extracellular matrix, all of which are closely related among 
themselves, with the CSC phenotype (Figure 1). The tumor microenvironment 
was mostly seen as a potential advantage in the past since it enhances the 
permeability and retention of the nano-sized drugs in the tumor (i.e. the EPR 
effect). However, tumor vasculature is highly irregular and could be tight in some 
regions, while being leaky in others. This irregular growth of tumor vasculature 
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also generates non-functional branches, leading to poorly irrigated regions that 
cannot be easily accessed with chemotherapy (Jain, 2005). Besides, the 
accumulation of stroma in the tumor and the high intratumoral pressure also 
prevent drug transport to the inner regions. A recent survey of the literature has 
indicated that only a 0.7% of the nanocarrier dose is delivered to solid tumors 
(Wilhelm et al., 2016), a results that suggests the failure of the overall concept 
of passive targeting as it is understood nowadays.  
Besides its barrier effect to drug delivery, the tumor niche also provides 
important signaling, often related to the cancer stem cell phenotype, that 
promotes tumor spreading and protection. CSCs and their niche have been 
recognized as critical features of cancer progression in the last years, and are 
currently in the focus of intense programs for drug development. Indeed, some 
prototypes have been developed to the stage of clinical implementation or are in 
advanced clinical trials (Figure 2). Most of the programs, however, are still 
focusing on separate aspects of CSCs and the TN, and as it will be illustrated in 
this review, those features are tightly interconnected (Figure 1) and might not be 




Figure 2. Advanced clinical trials (phase III or higher) of therapies against CSCs and/or their 
niche (only years 2011-2016). Further information on Supplementary Information (Table S1). 
Source: ClinicalTrials.gov (www.clinicaltrials.gov). 
 
The field of biomaterials and drug delivery, mostly in tissue engineering, has 
focused on pulsing important cell signaling routes, particularly those related to 
stem cell development, and understanding and mimicking the biological 
substrate (the “niche”). Concretely, scaffolds and other tissue engineering 
devices are frequently used to: (i) induce stem differentiation (Prabhakaran et al., 
2009), (ii) deliver cell-cycle modulators (Nayab et al., 2007) , (iii) modulate the 
inflammatory niche (Lisignoli et al., 2006), (iv) modulate tissue vasculature 
(Stegemann and Nerem, 2003) and (v) induce extracellular matrix remodeling 
(Schneider et al., 2010). This spectrum of biological activity fits perfectly the 
requirements of a new generation of antitumorals capable of modulating CSCs 
and their niche. 
The objective of this review is to analyze the properties and implications of the 
CSC phenotype and the TN, and to cover the main therapies designed to address 
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these characteristics, focusing on the potential role of biomaterial-based 
technologies (i.e. implants, nanomedicines, etc.) in such therapies. 
Cancer stem cells 
Cancer stem cells (CSCs) have been defined as a cell subpopulation in the tumor 
bulk that possesses stem cell capacities. CSCs may be derived from adult stem 
cells or progenitor cells, but also from  terminally differentiated cells that 
undergo epigenetic changes (Marotta and Polyak, 2009)(Hermann et al., 2010). 
In any case, malignant cells take advantage of stem cell-specific signaling to 
drive tumor development. 
CSCs were isolated for the first time in the 1990´s in acute myeloid leukemia, 
and were named “tumor initiating cells” (TICs) because they were able to start 
by themselves a tumor. Later, CSCs were isolated in several types of solid tumors 
(colon, glioma, pancreatic, lung, breast etc.). The fundamental traits of CSCs can 
be listed as: (i) ability for self-renewal and tumor reactivation, even in the 
absence of growth signals; (ii) evasion of apoptosis by secreted factors; (iii) 
increased activity of drug efflux transporters that enhances their resistance to 
chemotherapy and radiation; (iv) quiescence; (v) capacity to differentiate into 
any cell of the tumor population; (vi) ability to migrate and metastasize to other 
tissues, and (vii) increased capacity for DNA repair (Wicha et al., 2006) (Kaiser, 
2015). From a molecular biology perspective, CSC traits are driven by the 
activation of specific signaling pathways (Table 1), many of them present also 
on non-pathological stem cells.  
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Pathway Mechanism Reference 
Hedgedog (Hh) Cell proliferation, differentiation, survival, self-
renewal, CSCs maintenance, epithelial 
mesenchymal transition (EMT). 
(Dean et al., 2005) 
(Lu et al., 2012) 
Wnt Cell proliferation, differentiation, self-renewal and 
migration. 
(Reya and Clevers, 
2005) (Takebe et 
al., 2015) 
Notch Cell proliferation, differentiation, self-renewal, 
communication cell-to-cell and apoptosis. 
(Liu et al., 2005) 
(Pannuti et al., 
2010) 
NF-κB Cell proliferation, migration and apoptosis (Dolcet et al., 2005) 
(Hoesel and 
Schmid, 2013)  
Table 1. Important cell signaling pathways implicated in the CSCs phenotype. 
The key implication of CSCs is that a reduced number of these cells have the 
capacity to regenerate the tumor. Therefore, any therapy that aims at successfully 
increasing survival needs to be effective in fully eliminating these cells, which 
are more resistant to conventional cytotoxic drugs. A corollary to this is that 
tumor reduction is only informative on the capacity of the drug to eliminate the 
bulk tumor cells, and might not correlate with medium or long-term survival. 
There are, however, some drugs that treat specifically CSCs, as described in 
seminal works in oncology (Clement et al., 2007)(Visvader and Lindeman, 
2008)(Hambardzumyan et al., 2008)(Zhao et al., 2009)(Wang et al., 2010)(Singh 
and Settleman, 2010)  (Merchant and Matsui, 2010)(Takebe et al., 2011)(Yu et 
al., 2012)(Pattabiraman and Weinberg, 2014)(Skvortsov et al., 2015)(Takebe et 
al., 2015)(Takebe et al., 2015). Although some overlapping is admitted, for 
clarity, we classify these CSCs-specific therapies by two action mechanisms: (i) 
CSC differentiation and (ii) targeting CSC signaling pathways. The most studied 
drugs that act by these two mechanisms are presented in the following sections, 
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together with biomaterial-based systems that have shown the capacity to enhance 
their activity in cancer models or at least improve their delivery profile.  
2.1 Differentiation therapy 
2.1.1. Retinoid derivatives 
Since cancer stem cells take advantage of specific cell programs to boost their 
malignancy, the CSC pool can be depleted by inducing differentiation towards a 
mature phenotype (Figure 3). The use of differentiation therapies is intrinsically 
linked with the discovery of CSCs in hematopoietic cancers, where the most 
studied drugs have been retinoid derivatives. The mechanism of action of 
retinoid derivatives is related to ALDH, an enzyme that oxidizes intracellular 
aldehydes and retinol to retinoic acid, which induces cell differentiation.               .           
 
Figure 3. The significance of treating cancer stem cells (CSCs). The figure illustrates the 
outcome of conventional cytotoxic therapies that eliminate the bulk tumour (orange cells) and 
spare CSCs (green cells) vs. the outcome of therapies specifically directed against CSCs. 
Tumors depleted from CSCs might degenerate temporarily, but if some cells from the tumor 
bulk dedifferentiate cancer might recur. The combination of both strategies could lead to a more 
efficient elimination of the tumor. 
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Acute promyelocytic leukemia (APL) has benefited the most from treatments 
based on inducing cell differentiation. All-trans retinoic acid (ATRA) has 
dramatically turned APL therapy, and has further benefited from the introduction 
of another differentiation and pro-apoptotic agent, arsenic trioxide, that is given 
as a combined therapy with ATRA (Spira and Carducci, 2003). Traditionally 
considered a lethal disease, APL is nowadays one of the most treatable cancers, 
with the ATRA/arsenic trioxide combination achieving around 90% 
remissions.  Other cancers where retinoid-based differentiation  could be useful 
are melanoma, teratocarcinoma, squamous cell carcinoma, neuroblastomas and 
colon carcinoma, although the clinical efficacy of these treatments is still under 
investigation (Leszczyniecka et al., 2001)(Kawamata et al., 2006).   
ATRA has been encapsulated in several advanced formulations to address its low 
aqueous solubility and improve its stability, to enable its controlled release, to 
reduce hematological toxicity, and to improve its pharmacokinetic profile in 
vivo. These formulations include microemulsions, nanoparticles and liposomes. 
Liposomal formulations have reached clinical trials (phase I and II) for the 
treatment of solid tumors (clinical trial references NCT00195156, 
NCT00005969 and NCT00003656). A microemulsion encapsulating ATRA was 
developed using PEGylated-phospholipids as surfactants, providing improved 
stability and solubility for the drug (Hwang et al., 2004). Similarly, different 
polymeric nanoparticle compositions have been tested for ATRA delivery, most 
based on PEGylated polymers that prolong circulation time and optimize tumor 
targeting. These nanoparticles offer more opportunities for controlling drug 
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release; for example poly(ε-caprolactone)-poly(ethylene glycol) (PCL-PEG) 
nanoparticles showed controlled release of ATRA, and the pharmacokinetic 
profile of the formulation could be modified through changes in the polymer 
molecular weight, drug loading and polymer concentration (Jeong et al., 
2004). Encapsulation of ATRA in nanocarriers is also beneficial to prevent the 
hemolysis produced by the free drug (Lim et al., 2004), and to improve the 
antitumoral activity in vivo, an effect probably associated to the improved 
pharmacokinetic and biodistribution profile (Mehta et al., 1994)(Hwang et al., 
2004)(Jeong et al., 2004)(Li et al., 2011).  
Because ATRA only induces the differentiation of the CSCs, it is necessary to 
combine it with other drugs as it is done in the clinical setting to get total relapse 
of the tumor. Nanocarriers are ideal platforms to host multiple drugs, and poly-
lactic acid -poly(ethylene glycol) (PLA-PEG) nanoparticles have been loaded 
with ATRA and doxorubicin to get a synergistic effect that targets both CSCs 
and the bulk tumor cells. This effect was found to be stronger than that achieved 
by the co-administration PLA-PEG nanoparticles encapsulating both drugs 
separately, and markedly better than the monotherapies formulated in 
nanoparticles (Sun et al., 2015). 
2.1.2. TGF-β superfamily modulators 
Other strategy to induce differentiation is based on the premise that CSCs are 
sensitive to developmental signaling such as bone morphogenetic proteins 
(BMP) and transforming growth factor-beta (TGF- beta) inhibitors. The actions 
of BMP-signaling are complex and cell-specific, often resulting in contradictory 
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outcomes in different cancers (Kallioniemi, 2012). However, for some tumors 
BMP-signaling shows marked capacity to stop tumor proliferation and to drive 
CSCs towards more benign phenotypes, potentially treatable by conventional 
chemotherapy (Gonzalez-Gomez et al., 2014). Another member of the same 
signals superfamily, TGF-β, has been unveiled as an important inductor of CSCs 
stemness, as a regulator of the epithelial-mesenchymal transition (EMT) and as 
a promoter of CSC self-renewal. Treatments with TGF-β inhibitors result in 
reduced CSC markers in the tumor and in cell  migration (Anido et al., 
2010)(Singh and Settleman, 2010).  
Advanced formulations for BMPs have been designed for managing 
glioblastoma stem cells. The therapeutic concept here was the generation of a 
local reservoir for the controlled release of the CSC suppressor BMP-7, which 
could be implanted at the time of primary tumor resection. The controlled release 
properties of this formulation are essential due to the physiological half-life of 
BMP-7 that is limited to a few minutes.  A poly(lactic-co-glycolic acid) (PLGA) 
microsphere formulation was optimized towards this aim, where BMP-7 was 
encapsulated in the form of a nanocomplex with heparin and poloxamine. The 
formulation achieved over 90% encapsulation, minimal burst  and sustained 
BMP-7 release for over two months in bioactive form  (Reguera-Nuñez et al., 
2014). Further in vivo studies using human primary glioblastoma stem cell lines 
confirmed that the implantation of this formulation was able to activate the BMP-
canonical pathway in the tumor for over two months, and that this activation 
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results in reduced tumor development and downregulation of malignancy 
markers related to the CSC phenotype  (Figure 4) (González-Gómez et al., 2015). 
 
 
Figure 4. BMP-7 microspheres decreased tumor growth in a primary human glioblastoma stem 
cell xenograft model. Three groups were compared, blank microspheres (Blank MPs), and 
microspheres loaded either with 0.01% or 0.05% (w/w) BMP-7 (0.01% BMP7 MPs and 0.05% 
BMP7 MPs, respectively). (A) Representative picture of the tumors on the last day of the 
experiment.  (B) Tumor volume measured at different times. (C) Final tumor volume 
measurements. *p < 0.05. Reproduced from (González-Gómez et al., 2015) under a Creative 
Commons Attribution License. 
2.2 Targeting CSC signaling pathways 
In general, CSCs are considered as hyper-resistant to chemotherapy. However, 
due to their intrinsic signaling pathways, some molecules might have specific 
effects on CSCs. These molecules generally have broad effects in cell function, 
but most converge towards an apoptotic effect in the CSCs. We will cover here 
the most relevant examples of these drugs, which include Hedgehog, Wnt, NF- 




2.2.1 Hedgehog pathway inhibitors 
The Hedgehog pathway inhibitor HPI-1 has shown promising activity for 
suppressing CSCs (Coni et al., 2013), but its clinical use is limited by low 
aqueous solubility and bioavailability. To overcome these problems, HPI-1 has 
been encapsulated in PLGA-PEG nanoparticles (NanoHHI) (Chenna et al., 
2012). NanoHHI showed 3 to 4-fold higher oral and intraperitoneal 
bioavailability than the same drug in a conventional formulation (i.e. parent 
compound). NanoHHI showed marked suppression of tumor growth in vivo and 
the attenuation of metastasis. This advanced formulation showed a remarkable 
reduction of the CD133+ cell subpopulation, which is identified as the CSC pool 
(Y. Xu et al., 2012). Besides, NanoHHI has also been combined with 
gemcitabine, and this association was able to inhibit tumor growth without 
systemic toxicity in a pancreatic xenograft model (Chenna et al., 2012). 
2.2.2 Wnt inhibitors 
Wnt signaling regulates the proliferation, differentiation and survival of cancer 
cells, and can be divided into two pathways: canonical and non-canonical. The 
canonical pathway, also known as WNT-β-catenin pathway, is correlated with 
poor prognosis in cancer, and its inhibition reduces tumor progression through 
the downregulation of cell cycle proteins cyclin D1, c-Myc and c-jun (Persano 
et al., 2013) (Kahn, 2014). Inhibitors of the Wnt/β-catenin signaling pathway 
include antioxidants (quercetin, resveratrol, curcumin and EGCg), anti-
inflammatories (tetrandine, Sulindac) and other synthetic compounds (PRI-724, 
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OMP-18R5), some of them currently in clinical trials (Kahn, 2014)(Amado et 
al., 2014). 
Quercetin, resveratrol and tetrandrine are three validated Wnt inhibitors that 
share some biopharmaceutical and therapeutic limitations: low aqueous 
solubility, important toxicity and low oral bioavailability. Because of that, 
nanoformulations have been proposed with two aims: (i) to improve their 
biodistribution following i.v. administration and (ii) to improve their oral 
bioavailability. 
PEGylated nanocarriers have been the most used systems to improve the 
biodistribution of these molecules, although other carriers such as magnetic 
nanoparticles have also been investigated (Barreto et al., 2011). Among 
PEGylated nanocarriers, the most investigated formulations have been liposomes 
and nanoparticles based on biodegradable polyesters. PEGylated liposomes have 
been used to encapsulate quercetin and resveratrol, and these formulations have 
shown better pharmacokinetics, higher tumor accumulation, improved 
antitumoral effect and reduced toxicity in healthy tissues (Yuan et al., 2006) (X.-
Y. Lu et al., 2012). In order to get a synergistic cytotoxic effect, a second drug 
can be loaded in the liposomes. The combination of quercetin and vincristine 
produces higher effect than the monotherapy with either drug alone, and requires 
lower drug doses and has lower systemic toxicity (Wong and Chiu, 2011)(Sun et 
al., 2014). Resveratrol and curcumin were included in a liposomal 
formulation targeted with an antibody against HER-2, and the system showed 
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remarkable efficacy while decreasing the toxicity of the drugs (Catania et al., 
2013). 
Other important nanoformulations used to improve the biodistribution of Wnt 
inhibitors are core-shell type nanoparticles that have been used to deliver 
resveratrol and tetrandrine. Studies of resveratrol encapsulated in mPEG-PCL or 
PCL-PLGA-PEG nanoparticles and studies of tetrandrine encapsulated in 
polyvinylpyrrolidone-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles 
indicate that these nanoformulations improve the intracellular transport of these 
drugs and increase their therapeutic efficacy (Sanna et al., 2013)(Karthikeyan et 
al., 2013)(Xu et al., 2013) (Shao et al., 2009). In vivo studies, performed in a 
ectopic human ovarian tumor xenograft, with resveratrol–bovine serum albumin 
nanoparticles have shown higher accumulation of the drug in tumor, liver and 
kidney, and an increased pro-apoptotic effect as compared with the reference 
formulation (Guo et al., 2010). Nanoparticles can also be used to deliver drug 
combinations such as tetradrine with paclitaxel loaded in mPEG-PCL 
nanoparticles. This formulation enhanced reactive oxygen species (ROS) 
accumulation in the tumor and produced a higher pro-apoptotic effect in vitro 
(X. Li et al., 2012). 
Another objective of nanoformulations is improving oral bioavailability. A 
nanomicellar formulation of quercetin based on 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol (DSPE-PEG) has been 
developed, and it showed improved drug solubilization, protection of the drug 
from intestinal enzymes and enhanced drug permeability through the intestinal 
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barrier. An in vivo assay in a lung tumor xenograft mouse model showed 
significantly increased anti-tumor efficacy for quercetin nanomicelles compared 
to quercetin suspensions when administered orally (Chang et al., 2012). 
2.2.3  NF-kB inhibitors 
NF-kB signaling regulates the apoptosis, adhesion and migration of cancer cells, 
through a balance in the expression of pro-apoptotic proteins (FLICE-like 
inhibitory protein) and inhibitors of apoptosis (anti-apoptotic Bcl-2 family). 
Moreover, it also participates in the immune response against the tumor (Helbig 
et al., 2003)(Dolcet et al., 2005). Some inhibitors of this pathway are curcumin 
and disulfiram (Dolcet et al., 2005)(Zha et al., 2014) and both have been 
formulated in nanocarriers, but with different objectives. 
Curcumin is an inhibitor of NF-kB, but also transduces its effect through other 
networks such as Wnt, covered before. Curcumin has a plethora of interesting 
properties for cancer since it is pro-apoptotic, antiangiogenic, anti-inflammatory, 
immunomodulatory and antimitogenic. Curcumin is also poorly soluble in water 
and this conditions its oral bioavailability, a limitation that has been addressed 
by its incorporation into mucoadhesive systems, concretely polyacrylic acid-
based nanoparticles (Lim et al., 2011) and stearic acid-g-chitosan micelles 
(Wang et al., 2012). These systems have shown the capacity to improve 
curcumin solubilization and bioavailability. Importantly, they are also able to 
improve the pro-apoptotic, antitumoral effect of the drug following oral 
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administration while reducing systemic side effects. In vivo studies also 
confirmed a specific effect on the CSC subpopulation (Wang et al., 2012).  
In the case of disulfiram, its effects are dependent on the presence of copper in 
the medium (P. Liu et al., 2012), and for this reason, their co-encapsulation is  
advantageous. A liposomal formulation of disulfiram and copper in liposomes 
has been developed and has shown extended plasma half-life as compared to the 
free drug. The liposomal disulfiram/copper formulation also had antitumoral 
effect in mice breast cancer xenografts and minor systemic toxicity in vivo (Liu 
et al., 2014). 
2.2.4 PI3K/Akt/mTOR inhibitors 
The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin 
(mTOR) network is an essential pathway for cell proliferation, differentiation 
and survival, and is considered critical for CSC function (Xia and Xu, 2015). 
Rapamycin is the classical inhibitor of this pathway, although currently there are 
several new and more specific compounds in clinical trials (Benjamin et al., 
2011). Rapamycin has low water solubility, low specificity for tumor cells and 
important side effects. For these reasons, several nanoformulations for this drug 
have been tested, mostly based on PEGylated polyester nanoparticles and 
liposomes. 
PEGylated polyester micelles based on PLA or PCL have been developed for 
rapamycin delivery. In general, rapamycin in PEGylated micelles has better 
solubility,  intracellular uptake and anti-proliferative effect (Chen et al., 2013). 
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Rapamycin delivered in PEGylated micelles also enhances the efficacy of 
concomitant radiotherapy (Woo et al., 2012) and paclitaxel administration (Tian 
et al., 2015)(Mishra et al., 2013). In vivo, PEG-PCL micelles have demonstrated 
higher accumulation ratio of both drugs in the tumor compared to the 
accumulation in liver and spleen. Rapamycin and paclitaxel encapsulated in 
PEG-PCL micelles can suppress tumor growth completely in a breast cancer 
murine model by acting specifically through the mTOR pathway (Blanco et al., 
2014).  
Rapamycin has been encapsulated in PEGylated liposomes in combination with 
the cytotoxic drug paclitaxel. This formulation was more effective in vitro than 
any or the combination of the free drugs. In vivo results confirmed that the 
nanoformulation was effective in controlling tumor growth in a breast cancer 
murine model (Eloy et al., 2016). 
Another interesting drug association is that of rapamycin and perifosine, 
integrated in albumin-bound nanoparticles. An in vivo study in a multiple 
myeloma murine model indicated mutual suppression of the PI3K/Akt/mTOR 
pathway by rapamycin and perifosine, inducing synergistic tumor cell 
elimination in multiple myeloma xenograft mouse model (Cirstea et al., 2010). 
Rapamycin biodistribution can also be improved through the active targeting of 
the nanocarriers. PLGA nanoparticles targeted with a EGFR-antibody on their 
surface showed better cellular uptake and a superior anti-proliferative activity 





3.1 Aberrant Vasculature 
The formation of abnormal blood and lymphatic vessels is one of the critical 
hallmarks of solid tumors, which is driven by the secretion of high concentrations 
of angiogenic factors by the tumor cells. On one hand, the role of this abnormal 
vasculature is the nutrition and oxygenation of the tumor, but it also has a 
regulatory role in the secretion of growth factors and cytokines that spur tumor 
growth. Tumor-induced angiogenesis results in different vessels from those in 
normal vasculature as they are more tortuous, irregular and highly permeable, 
even to large proteins (Anderson et al., 2000). The irregularity of the vessels 
generates sometimes non-functional branches (Baluk et al., 2005), while in other 
cases, the interstitial pressure strangles functional vascular branches. This leads 
to areas with poor irrigation within the tumors that explains the resistance to 
radio- and chemotherapy (Jain, 2005). Besides, these low perfusion areas result 
in hypoxic microenvironments that will be the subject of a further section in this 
manuscript (section 3.3). There are several molecules implicated in the 
regulation of angiogenesis. The most prominent are: the vascular endothelial 
growth factor family (VEGF), pigment epithelium-derived factor (PEDF) and 
basic fibroblast growth factor (b-FGF) (Carmeliet and Jain, 2000).  
Targeting the vascular niche is advantageous because: (i) tumor endothelial cells 
are homogenous across different tumors, and they are less prone to genetic 
instability than cancer cells, and (ii) the tumor vascular endothelium is accessible 
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to systemically administered drugs and thus, does not require drug transport 
through the tumor tissue. Because of these advantages, it is in principle more 
straightforward to design biological-based therapies (e.g. monoclonal 
antibodies) towards these targets, and reduce the cytotoxic side effects associated 
to conventional chemotherapy that is directed against the tumor (Kobayashi and 
Lin, 2006).  
Traditionally, antiangiogenic therapies were aimed at completely destroying the 
tumoral vascular niche to deprive tumors from the oxygen and nutrients required 
for its growth. In the last decade, this concept has coexisted with that of “vascular 
normalization”, where the active agents  ‘‘normalize’’ the abnormal vasculature 
to make it more efficient for oxygen and  drug delivery, avoiding drug resistance 
and the formation of the hypoxic niche (Jain, 2005) (Figure 5). Even though these 
concepts have different implications in overall therapy, they largely use the same 
active compounds and both mediate their effect by sabotaging the vascular niche. 
Therefore, within the particular scope of this review, we do not consider further 





Figure 5. The tumor vascular niche. Compared to physiologically organized vascular branches 
(left), tumor vasculature is chaotic and hyperthrophic (middle). This lack of organization leads 
to non-homogeneous oxygen supply, and the formation of hypoxic regions. Anti-angiogenic 
therapies can eliminate tumor vasculature, but in excess, they can promote hypoxia and the 
acquisition of a CSC phenotype. At controlled doses, these compounds can “normalize” tumor 
vasculature (right), resetting physiological organization, improving drug delivery and 
destroying the nurturing features of the perivascular niche for CSCs. 
 
Targeting the vascular niche can be achieved through two possible strategies: (i) 
interfering with pro-angiogenic molecules, their receptors or downstream 
signaling, or (ii) upregulating or releasing endogenous inhibitors. The 
conventional therapy used in the clinic for this purpose is based on anti-VEGF 
monoclonal antibodies (bevacizumab), tyrosine kinase inhibitors such as 
imatinib, sorafenib, sunitinib, or combinations of them (Al-husein et al., 2012). 
Some of these molecules have already reached extended clinical use that is 
expected to expand even further as the results from many clinical trials validate 
their potential in many other indications (Figure 2).  
Biomaterial-based therapies against the vascular niche have also been 
investigated based on the same two strategies outlined above. As compared to 
other therapies, these systems try to provide added value fundamentally through 
their improved targeting. As mentioned before, molecular targets have a 
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particularly high exposure in the tumor endothelium, which makes actively 
targeted nanocarriers especially useful. Most drugs used for modulating tumor 
vasculature are non-selective by nature, and therefore, could benefit from 
encapsulation in an actively-targeted nanocarrier that increases the local 
concentration of the antiangiogenic agent, prolongs its release and decreases 
drug concentration at off-target sites. 
Even integrating active compounds that could be considered targeted such as 
antibodies, nanocarriers can provide some distinct advantages derived from the 
fact that many ligands increase cooperatively or synergistically their affinity 
when binding at several sites or by several receptors (“clustering”). This effect 
has spurred the interest on investigating multivalent carriers where ligand 
spacing is optimized for ligand-receptor interaction (Yu et al., 2010). In 
summary, actively-targeted nanocarriers could have the main benefit of 
concentrating both specific ligands and a high drug payload in distinct carriers. 
Another region of interest in the solid tumor vascular system are lymphatic 
vessels, whose defective function contribute to the enhanced tumor interstitial 
pressure (Padera et al., 2004), but also constitutes a possible route of metastatic 
cell spreading (Swartz and Skobe, 2001)(Hirakawa, 2009). To maximize 
lymphatic drainage of drug nanocarriers after subcutaneous administration, it is 
important to optimize their physicochemical properties, which should comprise 
a highly passivated surface and small particle size (Abellán-Pose et al., 2015). 
Moreover, Abellán-Pose et al. have studied the biodistribution of poly-glutamic 
acid-poly(ethylene glycol) (PGA-PEG) nanocapsules loaded with docetaxel 
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upon i.v. administration in a mice model, and observed that maximum 
extravasation to the lymphatic vessel was obtained with particles below 150 nm 
(Abellan-Pose et al., 2016). This prototype has been administered in a metastatic 
lung cancer murine model and has shown higher effect than the commercial 
formulation Taxotere® both in the primary tumor and in the lymphatic metastasis 
(Borrajo et al., 2016). Nanocarriers can also be actively targeted to the 
lymphatics by conjugation with VEGFR-3, podoplanin, and the hyaluronan 
receptor LYVE-1 (Hirakawa, 2009)(Swartz and Skobe, 2001). 
3.1.1 Nanocarriers that interfere with pro-angiogenic signaling 
VEGF is the main factor that promotes angiogenesis, thus blocking this signaling 
pathway is an attractive strategy to modulate tumor vasculature. Gold and silver 
nanoparticles have intrinsic antiangiogenic properties because of their 
interaction with endothelial heparin-binding glycoproteins associated to the 
VEGF receptor that inhibits their activity (Gurunathan et al., 2009)(Mukherjee 
et al., 2005). Moreover, gold nanoparticles bind vascular permeability factor and 
b-FGF, which are two other angiogenic mediators. These mechanisms result in 
inhibited endothelial and fibroblast proliferation (Mukherjee et al., 2005). Other 
metallic nanoparticles with antiangiogenic properties are silver and cerium oxide 
nanoparticles. These nanoparticles have the capacity to modify ROS intracellular 
levels, inhibiting the PI3K/Akt/mTOR pathway. The inhibition of this pathway 
reduces the production of pro-angiogenic growth factors, including VEGF and 
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FGF, ultimately reducing cell invasion and migration (Gurunathan et al., 
2009)(Giri et al., 2013)(Kosmidou et al., 2001). 
Gene therapy is another option for the design of antiangiogenic therapies, and 
several groups have designed nanocarriers for silencing the gene expression of 
VEGF. For instance, He et al. designed an efficient calcium carbonate 
nanocarrier for abrogating VEGF expression in colon cancer (He et al., 2008)(He 
et al., 2009). In another study, a siRNA against a VEGF receptor was included 
in alginate-modified polyethyleneimine (PEI) nanoparticles. These nanoparticles 
were designed to profit from the complexing and endosomal escape properties 
of PEI, but improving the efficacy/toxicity ratio of carriers through mixing with 
alginate (Li et al., 2014). Sakurai et al. have also designed liposomes to silence 
VEGFR2, composed by a pH sensitive cationic lipid, known as YSK05, and 
conjugated with an integrin ligand αvβ3 (cRGD). In vivo assays showed a 
selective action in tumor endothelial cells, but no effect in normal endothelial 
cells. This formulation also produced a reduction in the tumor volume in a renal 
cell carcinoma mouse model (Sakurai et al., 2013). 
In recent decades, the antiangiogenic effect of glucocorticoids (GCs) has also 
been described.  GCs are implicated in transcriptional responses to the majority 
of inflammatory, angiogenic, immunomodulatory and apoptotic genes, either by 
binding directly to DNA or to transcription factors involved in gene 
regulation.  The antiangiogenic effect of GCs is mainly achieved by 
downregulating the secretion of pro-angiogenic factors. To reduce the toxicity of 
GCs, these molecules have been encapsulated in PEGylated-liposomes. 
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Concretely, four different GCs were encapsulated in this system: budesonide, 
dexamethasone, methylprednisolone, and prednisolone. Liposomes efficiently 
delivered the GCs to the tumor, reduced the system side effects, and prolonged 
tumor growth inhibition. Budesonide encapsulated in liposomes resulted the 
most potent regarding their antiangiogenic effects.  Liposome PEGylation was 
critical to realize this prolonged drug circulation and to achieve enhanced drug 
extravasation to the tumor in a melanoma murine model (Banciu et al., 
2006)(Banciu et al., 2008). 
3.1.2 Nanocarriers that enhance antiangiogenic signaling 
Pigment epithelium-derived factor (PEDF) is a protein that has antiangiogenic, 
anti-inflammatory, antitumoral and antioxidant effects (Ek et al., 2006)(Ek et al., 
2007)(J. T. Liu et al., 2012). Therefore, several works in the literature have 
attempted to deliver this protein, frequently in the form of gene therapy.  Dass et 
al. described the first delivery system for a cancer therapy based on a PEDF, 
which was based on chitosan microparticles loaded with a PEDF-encoding 
plasmid. Animals treated with this therapy showed a reduction in bone lysis and 
in tumor progression, as observed in an osteosarcoma mouse model. Moreover, 
it also showed a reduction in the number of lung metastases, probably due to 
reduced invasiveness of the cells (Dass et al., 2007).  After this first report, other 
nanocarriers were also developed from PLGA, PEI and their PEGylated 
analogues (Cui et al., 2010)(L. Li et al., 2012)(Xu et al., 2016). Targeting 
moieties can also be added on these nanoparticles to improve selective 
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accumulation at the tumor site. For example, PEG–PEI nanoparticles conjugated 
to the integrin ligand αvβ3 (cRGD)  showed  enhanced  transfection efficiency 
in comparison with non-targeted PEG–PEI nanoparticles, despite of a worse 
capacity to complex DNA (L. Li et al., 2012).  
A combined therapy based on paclitaxel and PEDF-encoding plasmid, both 
loaded in PEG−PLGA nanoparticles was described by Xu et al. In vivo 
experiments indicated a superior anticancer effect for nanoparticles containing 
the combined therapy as compared to nanoparticles loaded with the drugs 
separately. Specifically, the combined therapy reduced tumor weight and 
improved survival in a colon adenocarcinoma mouse model. This positive effect 
was accompanied by a clear reduction on the tumor  microvessel density (L. Li 
et al., 2012)(Xu et al., 2016). 
Another molecule with antiangiogenic activity is TNP-470, a fumagillin 
analogue that is considered to be one of the most potent and broad-spectrum 
angiogenesis inhibitors (Satchi-Fainaro et al., 2005)(Benny et al., 2008). TNP-
470 has been conjugated to a N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymer to prolong its plasma half-life after intravenous administration and to 
improve its biodistribution by passive targeting mechanisms. Indeed, 
conjugation to HPMA prevents drug transport across the blood brain barrier 
(BBB), reducing the neurotoxicity typical of the free drug in glioblastoma, 
melanoma, pancreatic adenocarcinoma and breast cancer mouse models (Satchi-
Fainaro et al., 2004)(Satchi-Fainaro et al., 2005). TNP-470 has also been 
encapsulated in mPEG-PLA micelles to improve its solubility and to enhance its 
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intestinal absorption. An in vivo study in a murine melanoma model showed that 
the micellar formulation achieved good oral bioavailability and sustained plasma 
levels of the drug (Benny et al., 2008). 
3.2 Aberrant Extracellular Matrix 
The extracellular matrix (ECM) is responsible for maintaining the architecture 
and homeostasis in normal  tissue and it serves as support for tissue specific cells, 
immune cells, capillaries and fibroblasts (Kalluri and Zeisberg, 2006). It is 
composed by proteins (i.e. collagen, elastin and fibronectin) and polysaccharides 
such as hyaluronic acid and proteoglycans (i.e. perlecan, agrin, syndecans and 
glypicans) (Kim et al., 2011)(P. Lu et al., 2012). Cells bind to the ECM through 
functional structures, integrins, and the mechanical forces transduced can have 
important signaling roles (Geiger et al., 2001). The ECM also has polysulfated 
regions to bind growth factors and other signaling proteins, and acts as reservoir 
of these molecules whose release is triggered by ECM degradation (Schultz and 
Wysocki, 2009). Globally, both growth factor binding, release and cell-ECM 
interactions have critical roles in cancer development. In cancer, the ECM is 
deregulated, disorganized and enriched in pro-tumoral molecules (Figure 6) 
(Cox and Erler, 2011)(Oskarsson, 2013). From a therapeutic standpoint, the 
ECM in the CSC niche raises two issues. First, ECM components in conjunction 
with enhanced intratumoral pressure hinder drug movement and protect CSCs 
from chemotherapy. The second issue is that the highly dynamic ECM 
environment promotes tumor development through increased signaling and 
could favor cancer cell migration (P. Lu et al., 2012)(Oskarsson, 2013). 
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Biomaterial-based technologies to modulate both of these properties are 
currently under investigation. 
 
Figure 6. Tumoral extracellular matrix (ECM) has distinct features that contribute to tumor 
development. These include disorganized collagen fibers and high concentrations of ECM-
degrading enzymes (metalloproteinases) that trigger the release of growth factors from cryptic 
ECM-sites. The ECM hosts other non-tumoral cells such as tumor-associated macrophages 
(TAMs) and carcinoma-associated fibroblasts (CAFs) that contribute to the properties of the 
TN. 
3.2.1 Biomaterials that modulate ECM permeability 
Collagen IV, one of the principal constitutes of ECM, interacts anomalously with 
proteoglycans in cancer. Proteoglycan concentration is also higher in tumor than 
in normal tissue, and this feature is directly correlated with tumor aggressiveness 
(Iozzo and Sanderson, 2011). These characteristics result in a compact ECM that 
constitutes a physical barrier for drug transport, and particularly for 
macromolecules (Netti et al., 2000). For regional delivery routes, the hindrance 
to drug transport can be reduced by co-administration of ECM degrading 
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enzymes (e.g. collagenase or hyaluronidase). Unfortunately, this strategy cannot 
be easily implemented for intravenous administration, since the enzymes would 
be distributed throughout the body. Alternatively, these enzymes could be 
integrated onto the surface of nanoparticles. As a proof-of-concept, Goodman et 
al. have reported the bioconjugation of collagenase on polystyrene nanoparticles. 
The 100 nm polystyrene nanoparticles with collagenase showed four times 
higher transport through the ECM than 100 nm albumin-coated nanoparticles in 
vitro, in a multicellular spheroid culture of human cervical carcinoma (Goodman 
et al., 2007). The concept is pending of in vivo validation and of implementation 
in more pharmaceutically acceptable materials. 
Lysyl oxidase (LOX) is an enzyme that increases collagen cross-linking, thereby 
enhancing ECM rigidity. It is overexpressed in cancer (Kanapathipillai et al., 
2014), and therefore, its inhibition is a potential strategy to enhance the ECM-
penetration. LOX inhibiting antibodies have been conjugated onto PLA-PEG 
nanoparticles. In vivo studies, in an orthotopic breast cancer mouse model, 
revealed that antibody-nanoparticle conjugates have a higher enzyme inhibitory 
effect and lower toxicity than the free antibody. In addition, the tumor treated 
with the antibody-nanoparticle conjugates exhibited lower stiffness than those 
treated with the free antibody. The enhancement in efficacy observed for the 
nanoparticle conjugate allowed a 15-fold reduction of the administered dose, and 
is likely a consequence of ligand clustering effect (Kanapathipillai et al., 2012). 
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3.2.2 Biomaterial-based devices to suppress ECM-mediated 
protumoral signals 
Matrix metalloproteinases are enzymes that degrade the ECM, and are involved 
in cell proliferation, migration, and tumor development. These enzymes need the 
presence of Cu or Zn ions to preserve their catalytic properties. Treatments to 
prevent tumoral ECM remodeling are based on matrix metalloprotease inhibitors 
such as chelating agents capable of sequestering the metal ions from the enzymes 
active-sites. Some investigated metalloprotease inhibitors include β-
aminopropionitrile (Cox and Erler, 2011), marimastat (Rosenbaum et al., 
2005)(Goffin et al., 2005) and batimastat (Rintoul and Sethi, 2002). Another 
example is doxycycline, an antibiotic that non-selectively inhibits 
metalloproteinases by an unknown mechanism. Administration of these agents 
is limited by significant side effects, because metalloproteases are also mediators 
of platelet and endothelial function, and participate in other processes such as 
scarring, inflammation and atherosclerosis. Considering the severe side effects 
of metalloproteinase inhibitors, the benefits of integrating these agents in 
selective delivery systems is clear. For instance, liposomes and Eudragit-based 
nanoparticles encapsulating doxycycline showed no toxicity, but were able to 
induce clear metalloprotease inhibition in vitro (Yücel et al., 2013).  
3.3 Hypoxic foci 
While tumors are characterized by extensive vascularization, the presence of 
aberrant, non-functional vascular branches and poor blood flow derived from the 
high intratumoral pressure often generate hypoxic foci inside the tumor (Figure 
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7). This feature is important because presence of tumor hypoxia is linked to poor 
clinical prognosis (Vaupel and Mayer, 2007). Indeed, several studies have shown 
that activation of hypoxia-related intracellular signaling results in higher 
expression of efflux pumps, reduced pro-apoptotic signaling, and higher 
tendency towards quiescence (Cosse and Michiels, 2008). Tumor cells in 
hypoxic regions are more resistant to radiotherapy since the generation of ROS 
that mediates its effect is hindered due to the reductive environment (Keith and 
Simon, 2007)(Bartholomeusz et al., 2009).  Tumor cells under hypoxia are also 
more aggressive and have higher tendency for metastasis. All these unfavorable 
features are related to the acquisition of an undifferentiated, stem cell-like 
phenotype with a gene expression pattern that is a direct target of the intracellular 
transduction signals of hypoxia (Heddleston et al., 2009). 
 
 
Figure 7. The hypoxic niche. Irregular or non-functional branches generate regions 
characterized by low oxygen tension (hypoxia) that promote a CSCs phenotype. CSCs are also 





The cellular response to hypoxia is mediated by hypoxia inducible factors 
(HIFs). There are two types of HIFs, HIF-1 and HIF-2, and they are composed 
by 2 subunits: α (catalytic subunit) and β (constitutively expressed subunit). The 
function of HIF-1α is to regulate the cellular adaptation to low oxygen levels, 
including the survival of tumor cells under hypoxic conditions.  HIF-1α activates 
the transcription of genes involved in angiogenesis, glycolytic metabolism, 
reduced oxygen consumption, cell migration, and tumor cell invasion (Rapisarda 
et al., 2009). Under normoxic conditions HIF-1α is hydroxylated and interacts 
with the tumor suppressor Von Hippel−Lindau (VHL) protein, which produces 
the degradation of the factor inside the proteasome. When cells are in hypoxic 
conditions, non-hydroxylated HIF-1α translocates to the nucleus where it 
activates the transcription of numerous target genes (Lu et al., 2009)(X. Q. Liu 
et al., 2012). HIF-2α participates in the regulation of stem cell self-renewal and 
multipotency, but it is expressed only in some specific cell types (Keith and 
Simon, 2007). HIF-2α acts through Oct4, the key transcription factor regulating 
cell “stemness” (Mohyeldin et al., 2010)(Seidel et al., 2010). 
Two major therapeutic approaches are being investigated to counteract hypoxic 
effects. From a clinical standpoint, the more advanced option is the use of 
vascular normalization agents (see Section 3.1), which are supposed to improve 
perfusion homogeneity under controlled conditions. Vascular normalization has 
demonstrated to improve vessel lining and its maturation, resulting in enhanced 
tumor perfusion and oxygenation, together with inhibited tumor cell invasion, 
intravasation, and metastasis. Furthermore, the good oxygenation of the tumor 
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improves its sensitivity to the chemotherapy and radiation (Mazzone et al., 
2009).  
The second strategy relies on the selective inhibition of HIFs. Since these are 
intracellular proteins, interfering RNA strategies based on siRNAs or miRNAs 
have been the most frequently investigated (Piao et al., 2012)(Bartholomeusz et 
al., 2009). The major problem of RNA interference is the delivery of the 
therapeutic sequence to the cell cytosol, and due to this reason, nanocarriers have 
a major role in these therapeutic strategies (Thomas et al., 2003). Liu et al. 
designed cationic micellar nanocarriers composed by a combination of amino-
phosphate poly(ε-caprolactone)-block-poly(2-aminoethylethylene phosphate) 
(PCL-b-PPEEA) and poly(ε-caprolactone)-block-poly(ethylene glycol) (PCL-b-
PEG), and used these materials to complex siRNA against HIF-1α. In vitro 
studies showed that these micellar systems inhibit HIF-1α, and by this 
mechanism, they reduce the secretion of proangiogenic factors, tumor growth 
and cell migration. A synergic antitumoral effect was observed in vivo, when 
these micelles were administered in combination with doxorubicin in a prostate 
tumor xenograft model (Allen et al., 1998)(X. Q. Liu et al., 2012). SiRNA 
targeting HIF-1α has also been formulated in a new biodegradable copolymer, 
D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactone-ran-
glycolide). In vivo experiments in a xenograft nasopharyngeal carcinoma 
murine model confirmed that the nanoparticles did not produce a cytotoxic effect 
per se, but were able to decrease 2-fold the expression of HIF-1α in 24 hours. 
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This reduction in HIF-1α resulted in a proportional reduction in tumor volume 
(Chen et al., 2015). 
3.4 Inflammatory and immunosuppresive environment 
The tumor microenvironment contains heterogeneous non-tumoral cell 
populations that include both innate and adaptive immune cells  (Grivennikov et 
al., 2010). These immune cells have an important role in tumor development 
since they produce growth factors, cytokines, chemokines, prostaglandins and 
ROS (Barcellos-Hoff et al., 2013). Tumor-promoting agents, including 
CXCR4/SDF1α signaling and Gremlin-1-expressing mesenchymal stem cells 
(MSCs) that stimulate the recruitment of cells implicated in inflammation. 
Among these, immature myeloid cells and carcinoma-associated fibroblasts 
positive for α-smooth-muscle-actin are of special interest (Quante et al., 2011). 
Tumor associated-macrophages (TAMs) are also present in the tumoral niche 
during all the stages of tumor progression. Through the secretion of growth 
factors, chemokines, interleukins, enzymes and other mediators, these cells 
enhance the proliferation and invasion of cancer cells, promote angiogenesis, and 
trigger immunosuppressive effects that prevent the attack of natural killer and T-
cells (Noy and Pollard, 2014).  
The tumor microenvironment is particularly rich in pro-inflammatory molecules, 
mainly cytokines.  Cytokine receptors are present both bound to the cell 
membrane and in soluble form. They are transduced through G-proteins and 
regulate cell behavior including chemotaxis, growth, differentiation, and 
immune stimulation or immune suppression. Depending on the type of cytokine, 
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they can promote or inhibit cancer progression and metastasis (Dranoff, 2004). 
Chemokines are group of over 50 chemotactic cytokines with only 18 chemokine 
receptors, implying overlapping in ligand-receptor specificity. For cancer, the 
most important is CXCR4, a receptor with low expression in most healthy 
tissues, but overexpressed in many highly metastatizing tumors (Balkwill, 
2004)(Kang et al., 2005). The interaction of the CXCR4 ligand (CXCL-12) 
produces the activation of migratory, proliferative and survival signaling 
pathways (Wicha et al., 2006). Preclinical studies in several murine cancer 
models have shown that blocking these receptors reduces metastasis and tumor 
invasion (Liang et al., 2004)(Kakinuma and Hwang, 2006). 
Other important cytokines present in the tumor niche are interleukins (IL) 
(Dranoff, 2004), tumor necrosis factor-α (TNF-α) and interferons (IFNs) 
(Grivennikov et al., 2010)(West et al., 2015). These proteins have very diverse 
functionalities that result in pro- or antitumoral effects, depending on the specific 
cytokine and the concomitant signaling activated.   
Disconnecting the tumor immunosuppressive environment is a critical step to 
rescue immune responses against tumors, and is now considered a major strategy 
to fight cancer including metastasis. The main drug delivery strategies to 
reactivate immunity in the tumor are described below and are classified in: (i) 
biomaterials as “danger signals”, (ii) cytokine delivery systems, (iii) biomaterials 




3.4.1 Biomaterials as “danger signals” 
The integration of “danger signals” in biomaterials, i.e. toll-like receptor (TLR) 
ligands, is a method to stimulate the immune system. The presentation of such 
ligands can revert TAM polarization to an immunostimulatory phenotype and 
provide effective antitumoral cytotoxic responses through CD8+ T-cell 
activation. The most used “danger signal” is lipopolysaccharide (LPS) but others 
such as PolyI:C or CpG are also widely reported (Ali et al., 2014)(Goldberg, 
2015). 
PLGA and polyurethan-urea nanoparticles have been used to integrate TLR 
ligands tyrosine related protein 2 (TRP2), 7-acyl lipid A or LPS. The 
administration of these formulations in vivo, in a melanoma mouse model, 
resulted in antitumoral immune responses with recruitment of dendritic cells and 
increased secretion of pro-inflammatory cytokines (Hamdy et al., 2008)(Zhang 
et al., 2011). To produce a more localized immunostimulation with reduced 
systemic side effects, these particles can be targeted with antibodies against 
adhesion molecules present in inflamed endothelial cells (VCAM-1 and ICAM-
1) (Morral-Ruiz et al., 2013). If a potent, direct antitumoral effect is desired, a 
drug such as paclitaxel can be co-encapsulated with a LPS to obtain a synergistic 
effect. In vivo studies in a melanoma mouse model showed that treatment with 
nanoparticles with this combined therapy achieved a 40% reduction in tumor size 
compared to mice treated only with Taxol®. A clear improvement in animal 
survival was also observed (Roy et al., 2013). 
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Cationic polymers such as cationic dextran and PEI are also capable of 
interacting with TLRs and shifting TAMs polarization, resulting in higher IL-12 
expression. This effect reduces angiogenesis, produces immunoactivation, 
inhibits tumor progression, and ultimately, increases survival in murine cancer 
models (Huang et al., 2013). 
3.4.2 Cytokine delivery systems 
Cytokines have very short half-lifes in vivo, and therefore, it is critical to provide 
sustained levels to achieve a therapeutic effect. The two major ways to achieve 
these sustained levels are to use controlled release devices and/or to use gene 
therapies encoding these cytokines.  
IL-12 is a cytokine that can produce tumor regression by enhancing natural killer 
and cytotoxic T-lymphocyte activity. Due to this potent activity, IL-12 has been 
encapsulated in controlled release systems. Liu et al. designed implantable 
biodegradable gelatin hydrogels for subcutaneous delivery. This formulation 
showed controlled release of IL-12 over 12 days and efficient suppression of 
colon carcinoma growth in mice (Liu et al., 2003). Chitosan and cholesterol-
bearing pullulan nanoparticles have also been used for the controlled release of 
IL-12. These formulations showed low toxicity, capacity to induce antitumoral 
immunity, and the capacity to target metastasis in colon carcinoma murine model 
(Shimizu et al., 2008)(Q. Xu et al., 2012). 
IL-12 delivery is also interesting for combination therapy. For example, PLA 
microspheres loaded with IL-12, TNF-α and granulocyte-macrophage colony-
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stimulating factor (GM-CSF) were used as antitumoral therapy in a murine breast 
cancer model. The microspheres were administered by intratumoral injection, 
where they initiated a major infiltration of polymorphonuclear cells and CD8+ 
cytotoxic T-cells that resulted in increased the number of tumor free mice at the 
end of the study. This therapy also resulted in specific memory T-cells that could 
prevent tumor relapse in a murine model of breast cancer (Sabel et al., 2004).  
In another combined therapy case, Park el al. designed a liposome-type carrier 
loaded with IL-2 and the TGF-β antagonist SB505124. The concept was to 
combine IL-2 immunostimulation and SB505124 blockage of TGF-β mediated 
immunosuppression. These carriers were based on an innovative concept where 
both drugs were encapsulated in a photopolymerized nanogel, and this was 
subsequently coated by a PEGylated lipid bilayer. The liposome-type 
formulation was able to increase the cytokines´ half-life in circulation, to induce 
innate immunity and to inhibit tumor growth in melanoma-bearing mice  (Park 
et al., 2012). 
Nanoparticles are also frequently used for gene therapies aimed at inducing local 
cytokine expression due to their capacity to stabilize plasmids and improve their 
intracellular delivery. Examples of polymeric biomaterials used to improve the 
transfection of IL-12 encoding plasmids are the amphiphilic block copolymers 
poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) (Maheshwari et al., 2000) and 
poly(N-methyldietheneamine sebacate) (PMDS) (Wang et al., 2006).  The 
general idea was validated by Maheshwari et al. who encapsulated IL-12 coding 
plasmids in PAGA nanoparticles. The formulation showed activation of host 
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immunity and an antitumoral effect in a colon adenocarcinoma mouse model, an 
effect which could not be observed with the naked plasmid (Maheshwari et al., 
2000). In another study, PDMS-nanoparticles were used for combined therapy 
comprising an IL-12 encoding plasmid and paclitaxel. The results indicated a 
synergistic effect of the active agents, where enhanced tumor sensitivity to 
paclitaxel was achieved after a reduced number of administrations (Wang et al., 
2006). 
Another cytokine of interest for T-cell activation and cancer treatment is IL-18, 
and a nanoemulsion-based gene delivery strategy for sustained expression of this 
cytokine has already been reported. This nanoemulsion formulation was 
composed of the standard cationic lipids DOPE and DOTAP, the PEGylated 
surfactant Tween 80 and different oils. In a lung tumor mouse model, this 
formulation generated a stable system with higher transfection activity and 
higher capacity for T-cell activation than the commercial agent Lipofectamine 
(Kang et al., 2009). 
 
3.4.3 Biomaterials that inhibit chemotaxis 
Another important strategy to treat the inflammatory niche is to inhibit 
chemokine activity. Due to its relevance in many tumors, silencing CXCR4 
expression is a particularly interesting idea where interfering RNA strategies can 
play an important role. Abedini et al. associated CXCR4-siRNA to dextran-
spermine nanoparticle. This formulation was selected for its beneficial 
efficacy/toxicity ratio as compared to other reference materials (i.e. PEI and 
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DOTAP/cholesterol) tested in the same study (Eliyahu et al., 2005). A in vivo 
test performed in a colon carcinoma mouse model showed that these siRNA 
nanoparticles were able to produce improved CXCR4 inhibition as compared to 
the naked siRNA (Abedini et al., 2011)(Abedini et al., 2012).  
Another approach to inhibit CXCR4 is to use the synthetic drug antagonist 
perixaflor. Misra et al. designed PLGA-acrylate nanoparticles for the controlled 
release of this drug. The formulation has shown effective receptor inhibition in 
vitro, with a better dose/response curve than the free molecule (Misra et al., 
2015). 
3.4.4 Integrative systems 
Particularly powerful devices can be designed when biomaterials are used to 
integrate some of the elements described in the previous sections in a rational 
manner. An early example of this integration was provided by Hori et al. who 
included activated dendritic cells and IL-15 in an alginate gel for peritumoral 
injection in a mouse melanoma model. The matrix was able to reduce tumor size 
and improve survival (Hori et al., 2009). 
Some of the best devices for integrative immunomodulation, often involve the 
combined presence of “danger signals”, cytokine release and antigen 
presentation, all integrated in scaffolds that provide a cellular context. Ali et al. 
prepared PLGA-scaffolds loaded with GM-CSF, tumor cell lysates and CpG-
ODN. This scaffold produced an inmunostimulatory response that increased 
recruitment of CD8+ T-cells and production of proinflammatory cytokines in the 
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tumor and dendritic cells at the vaccination site. The device achieved a complete 
regression of the tumors and enhanced survival of mice bearing established 
melanomas. Finally, this study confirmed the synergic effect of the three 
elements of the immunomodulatory material (Ali et al., 2009). Afterwards, 
similar results were obtained with another prototype where CpG-ODN was 
changed for poly(I:C). In this study, the effect of the integrated system was 
compared with the intratumoral injection and the injection of the free 
components in a rat glioma model. Only the immunomodulatory material 
achieved complete tumor remission and improved mice survival. This result 
clearly indicates that the scaffold is not a passive substrate, but rather a part of 
immunomodulatory microenvironment that can surveyed by immune cells (Ali 
et al., 2011).  
Outlook and conclusions 
While there have been considerable advances in oncology over the last decades, 
several types of cancer still present very low survival rates. Many of these are 
the cancers where a tumor initiating cell subpopulation with stem cell-like has 
been reported. Despite the existence of this population, therapies that where 
under clinical development in the last decade failed to recognize the importance 
of cancer stem cells (CSCs), while they also neglected the importance of the 
main traits of the CSC niche including abnormal vasculature, hypoxia, ECM-
dysregulation and inflammation.  
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In the last years, the interest on CSCs has translated from the molecular biology 
laboratories to pharmaceutical industry and drug delivery science. Together with 
this change, there has been a wider recognition of the importance of the tumor 
niche that supports these CSC features. This has resulted in a very high number 
of therapies in clinical trials that are directed to CSCs for solid tumors, and even 
some therapies in clinical practice for leukemia. Many of these therapies, 
however, might face important challenges before they can advance towards 
medical use. Their main limitations are due to their sub-optimal delivery 
characteristics and the unmet necessity to be integrated in combined therapies, 
together with regulatory and industrial challenges. 
Delivery issues for these of therapies are important because many dysregulate 
signaling pathways or environmental features that, although critical for CSCs 
and their niche, can also affect other important populations such as non-cancer 
stem cells. Thus, side-effects for these therapies are almost inevitable, and 
delivery systems capable of improving selective drug biodistribution towards 
tumoral cells are a must. Additionally, many of these therapies combine this fine 
biodistribution requirements with fast degradation times. Such characteristics 
call for controlled release systems with active targeting, or if cell spreading can 
be neglected, to regional delivery using controlled release devices. This last 
concept has been the basis in CSC-specific strategies such as the use of 
controlled release microspheres for the regional delivery of BMP-7 in the 
treatment of glioblastoma (Reguera-Nuñez et al., 2014). On the other hand, gene 
therapy could be important to manipulate CSCs signaling pathways (Hedgehog, 
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Wnt, etc.) or effectors of environmental cues such as HIF. Gene therapy in the 
context of CSC treatment shares most of its challenges with other in vivo 
applications, with the provision that the nanotherapeutics need to reach the CSCs 
in their niche. Considering that CSCs are a minor part of the tumor, and that they 
are often in its most inaccessible regions, this becomes and additional difficulty. 
In general terms, any therapy that is not capable of being transported through the 
tumor ECM or that binds tumor cells non-selectively, will either be retained at 
the periphery of the tumor or will be absorbed by terminally differentiated cancer 
cells acting as sacrificial barriers. 
 Another future challenge of future therapies against CSCs and their niche is their 
necessity to be integrated in combined therapies to have substantial effects. Since 
cellular processes are typically redundant, any effect on a targeted pathway might 
be compensated by additional activation of other pathways. For drug 
combinations to be effective, however, it is critical that there is mechanistic 
cooperation or synergism between the two agents. Acute promyelocytic 
leukemia provides a clinically successful example of how a very potent 
differentiation agent (ATRA) would be ineffective without a pro-apoptotic 
inducing agent, since the cells would become resistant to this medication in a 
short time span. When combined with a proapoptotic agent, the cells 
differentiated by ATRA are easily removed before any resistance is generated. 
Such roles of combination with ATRA were traditionally provided by 
anthracycline-based agents, and since 2013, by arsenic trioxide that combines a 
pro-apoptotic with a further pro-differentiation effect.  
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Because of their intrinsic flexibility, biomaterial-based devices are ideal 
platforms for combined therapies. For instance, Sun et al. have taken advantage 
of a rationally selected drug combination (ATRA and doxorubicin) and a suitable 
delivery platform to deliver this combined therapy (Sun et al., 2015). A more 
sophisticated example of the use of biomaterials to maximize the therapeutic 
value of drug combinations is provided by the work of Mooney´s group, which 
combines anticancer vaccines, TLR agonists and controlled release of cytokines 
to design potent immunomodulatory materials. However, a critical aspect of 
these technologies is that the diverse elements are integrated within the context 
of a polymeric scaffold that helps to generate a regional environment.  The 
effects of these elements are thereby focalized while providing a mechanical and 
spatial context for the recruited immune cells (Ali et al., 2014). Because of their 
focus on stem cell differentiation, modulation of stem cell signaling and 
mimicking the cell microenvironment, tissue engineering devices can find 
surprising new applications in cancer suppression as it has been illustrated 
through some examples in this review.  
A final challenge for therapies directed to CSCs and their niche could come from 
regulatory authorities and industry. For these actors, an important issue would 
be identifying experimental outcomes during screening and preclinical 
experimentation that correlate with positive clinical endpoints. Cytotoxicity in 
cell panels and reduction of tumor volume are routinely used for anticancer drug 
screening, but are not necessarily indicative of CSC elimination and survival. 
Also, tumor niche modulation might not be able to eliminate the tumor by itself, 
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but could have instrumental effects in well-chosen combination therapies. 
Identifying and measuring the effects of these combinations at early stages and 
selecting combined therapies with great potential from less interesting ones, 
could prove to be difficult.  
Addressing cancer by suppressing the CSCs and their supporting niche is still far 
from being a validated general strategy. In the next years, there will be more data 
available from clinical trials of drug candidates aimed at addressing some of 
these relatively new aspects of tumor biology. We expect, however, that higher 
benefit will be achieved with combined therapies that address simultaneously the 
CSC phenotype and the niche, and probably, in the presence of another drug 
capable of eliminating differentiated tumor cells. Despite the open questions, it 
is already clear that the CSC phenotype and the tumor niche are essential features 
of cancer, and thus, it is reasonable to expect that addressing them will be 
essential for future therapies. In this sense, the design of devices capable of 
integrating these strategies in a coordinated and synergistic fashion could be 
critical to achieve maximum benefits. 
 
Acknowledgments 
The authors acknowledge funding from Fundación BBVA, Proyectos de 
Investigación en Biomedicina (2014-PO0110) and Ministerio de Economía y 
Competitividad (SAF2014-58189-R, FEDER Funds).  
Conflict of interest 




CGM and NC performed the bibliographic search. MGF designed the paper 
outline. All authors contributed to data analysis, writing and revision of the 
manuscript. 
References 
Abedini, F., Hosseinkhani, H., Ismail, M., Domb, A.J., Omar, A.R., Chong, P.P., 
Hong, P.-D., Yu, D.-S., Farber, I.-Y., 2012. Cationized dextran 
nanoparticle-encapsulated CXCR4 -siRNA enhanced correlation between 
CXCR4 expression and serum alkaline phosphatase in a mouse model of 
colorectal cancer. Int. J. Nanomedicine 7, 4159–4168. 
doi:10.2147/IJN.S29823 
Abedini, F., Ismail, M., Hosseinkhani, H., Ibrahim, T.A.T., Omar, A.R., Chong, 
P.P., Bejo, M.H., Domb, A.J., 2011. Effects of CXCR4 siRNA / dextran-
spermine nanoparticles on CXCR4 expression and serum LDH levels in a 
mouse model of colorectal cancer metastasis to the liver. Cancer Manag. 
Res. 3, 301–309. doi:10.2147/CMR.S11678 
Abellán-Pose, R., Csaba, N., Alonso, M.J., 2015. Lymphatic Targeting of 
Nanosystems for Anticancer Drug Therapy. Curr. Pharm. Des. 1194–1209. 
doi:10.2174/1381612822666151216150809 
Abellan-Pose, R., Teijeiro-Valiño, C., Santander-Ortega, M.J., Borrajo, E., 
Vidal, A., Garcia-Fuentes, M., Csaba, N., Alonso, M.J., 2016. 
50 
 
Polyaminoacid Nanocapsules for Drug Delivery to the Lymphatic System: 
Effect of the Particle Size. Int. J. Pharm. Accepted. 
doi:10.1016/j.ijpharm.2016.05.034 
Acharya, S., Dilnawaz, F., Sahoo, S.K., 2009. Targeted epidermal growth factor 
receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 
30, 5737–5750. doi:10.1016/j.biomaterials.2009.07.008 
Al-husein, B., Abdalla, M., Pharm, D., Trepte, M., Deremer, D.L., Somanath, 
P.R., Ph, D., 2012. Antiangiogenic Therapy for Cancer : An Update. 
Pharmacotherapy 32, 1095–1111. doi:10.1002/phar.1147 
Ali, O.A., Doherty, E., Bell, W.J., Fradet, T., Hudak, J., Laliberte, M.T., 
Mooney, D.J., Emerich, D.F., 2011. Biomaterial-based vaccine induces 
regression of established intracranial glioma in rats. Pharm. Res. 28, 1074–
1080. doi:10.1007/s11095-010-0361-x 
Ali, O.A., Emerich, D., Dranoff, G., Mooney, D.J., 2009. In situ regulation of 
DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 
1, 8ra19. doi:10.1126/scitranslmed.3000359 
Ali, O.A., Verbeke, C., Johnson, C., Sands, R.W., Lewin, S.A., White, D., 
Doherty, E., Dranoff, G., Mooney, D.J., 2014. Identification of immune 
factors regulating antitumor immunity using polymeric vaccines with 
multiple adjuvants. Cancer Res. 74, 1670–1681. doi:10.1158/0008-
5472.CAN-13-0777 
Allen, C., Yu, Y., Maysinger, D., Eisenberg, A., 1998. Polycaprolactone- b -poly 
( ethylene Oxide ) Block Copolymer Micelles as a Novel Drug Delivery 
51 
 
Vehicle for Neurotrophic Agents FK506 and L-685 , 818. Bioconjug. Chem. 
1802, 564–572. doi:10.1021/bc9702157 
Amado, N.G., Predes, D., Moreno, M.M., Carvalho, I.O., Mendes, F.A., Abreu, 
J.G., 2014. Flavonoids and Wnt/β-catenin signaling: Potential role in 
colorectal cancer therapies. Int. J. Mol. Sci. 15, 12094–12106. 
doi:10.3390/ijms150712094 
Anderson, S. a, Rader, R.K., Westlin, W.F., Null, C., Jackson, D., Lanza, G.M., 
Wickline, S. a, Kotyk, J.J., 2000. Magnetic resonance contrast enhancement 
of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn. 
Reson. Med. 44, 433–439. doi:10.1002/1522-
2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9 
Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., 
Carmona, M.A., Prieto-Sanchez, R.M., Barba, I., Martinez-S??ez, E., 
Prudkin, L., Cuartas, I., Raventos, C., Marinez-Ricarte, F., Poca, M.A., 
Garcia-Dorado, D., Lahn, M.M., Yingling, J.M., Rodon, J., Sahuquillo, J., 
Baselga, J., Seoane, J., 2010. TGF-beta Receptor Inhibitors Target the 
CD44high/Id1high Glioma-Initiating Cell Population in Human 
Glioblastoma. Cancer Cell 18, 655–668. doi:10.1016/j.ccr.2010.10.023 
Balkwill, F., 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4, 540–
550. doi:10.1038/nrc1388 
Baluk, P., Hashizume, H., Mcdonald, D.M., 2005. Cellular abnormalities of 




Banciu, M., Metselaar, J.M., Schiffelers, R.M., Storm, G., 2008. Liposomal 
glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 
melanoma-bearing mice. J. Steroid Biochem. Mol. Biol. 111, 101–110. 
doi:10.1016/j.jsbmb.2008.05.004 
Banciu, M., Schiffelers, R.M., Fens, M.H.A.M., Metselaar, J.M., Storm, G., 
2006. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 
melanoma in mice. J. Control. Release 113, 1–8. 
doi:10.1016/j.jconrel.2006.03.019 
Barcellos-Hoff, M.H., Lyden, D., Wang, T.C., 2013. The evolution of the cancer 
niche during multistage carcinogenesis. Nat. Rev. Cancer 13, 511–8. 
doi:10.1038/nrc3536 
Barreto, A.C.F., Santiago, V.R., Mazzetto, S.E., Denardin, J.C., Lavín, R., Mele, 
G., Ribeiro, M.E.N.P., Vieira, I.G.P., Gonçalves, T., Ricardo, N.M.P.S., 
Fechine, P.B.A., 2011. Magnetic nanoparticles for a new drug delivery 
system to control quercetin releasing for cancer chemotherapy. J. 
Nanoparticle Res. 13, 6545–6553. doi:10.1007/s11051-011-0559-9 
Bartholomeusz, G., Cherukuri, P., Kingston, J., Cognet, L., Lemos, R., Leeuw, 
T.K., Gumbiner-Russo, L., Weisman, R.B., Powis, G., 2009. In vivo 
therapeutic silencing of hypoxia-inducible factor 1 alpha (HIF-1) using 
single-walled carbon nanotubes noncovalently coated with siRNA. Nano 
Res. 2, 279–291. doi:10.1007/s12274-009-9026-7 
Benjamin, D., Colombi, M., Moroni, C., Hall, M.N., 2011. Rapamycin passes 




Benny, O., Fainaru, O., Adini, A., Cassiola, F., Bazinet, L., Adini, I., Pravda, E., 
Nahmias, Y., Koirala, S., Corfas, G., D’Amato, R.J., Folkman, J., 2008. An 
orally delivered small-molecule formulation with antiangiogenic and 
anticancer activity. Nat. Biotechnol. 26, 799–807. doi:10.1038/nbt1415 
Blanco, E., Sangai, T., Wu, S., Hsiao, A., Ruiz-Esparza, G.U., Gonzalez-
Delgado, C. a, Cara, F.E., Granados-Principal, S., Evans, K.W., Akcakanat, 
A., Wang, Y., Do, K.-A., Meric-Bernstam, F., Ferrari, M., 2014. 
Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances 
Synergistic Targeting of the PI3K/Akt/mTOR Pathway. Mol. Ther. 22, 1–
10. doi:10.1038/mt.2014.27 
Borrajo, E., Abellan-Pose, R., Soto, A., Garcia-Fuentes, M., Csaba, N., Alonso, 
M.J., Vidal, A., 2016. Docetaxel-loaded Polyglutamic acid-PEG 
Nanocapsules for the Treatment of Metastatic Cancer. Submitt. to J. 
Control. Release. doi:10.1016/j.jconrel.2016.07.048 
Carmeliet, P., Jain, R.K., 2000. Angiogenesis in cancer and other diseases. 
Nature 407, 249–257. doi:10.1038/35025220 
Catania, A., Barrajón-Catalán, E., Nicolosi, S., Cicirata, F., Micol, V., 2013. 
Immunoliposome encapsulation increases cytotoxic activity and selectivity 
of curcumin and resveratrol against HER2 overexpressing human breast 
cancer cells. Breast Cancer Res. Treat. 141, 55–65. doi:10.1007/s10549-
013-2667-y 
Chang, K.L., Tan, B., Chang, K.-L., Lim, B.K., Chiu, G.N., 2012. Perorally 
54 
 
active nanomicellar formulation of quercetin in the treatment of lung cancer 
Perorally active nanomicellar formulation of quercetin in the treatment of 
lung cancer. Int. J. Nanomedicine 7, 651–661. doi:10.2147/IJN.S26538 
Chen, Y., Xu, G., Zheng, Y., Yan, M., Li, Z., Zhou, Y., Mei, L., Li, X., 2015. 
Nanoformulation of D- α -tocopheryl polyethylene glycolide ) diblock 
copolymer for siRNA targeting HIF-1 α for nasopharyngeal carcinoma 
therapy. Int. J. Nanomedicine 10, 1375–1386. doi:10.2147/IJN.S76092 
Chen, Y.C., Lo, C.L., Lin, Y.F., Hsiue, G.H., 2013. Rapamycin encapsulated in 
dual-responsive micelles for cancer therapy. Biomaterials 34, 1115–1127. 
doi:10.1016/j.biomaterials.2012.10.034 
Chenna, V., Hu, C., Pramanik, D., Aftab, B.T., Karikari, C., Campbell, N.R., 
Hong, S.-M., Zhao, M., Rudek, M. a., Khan, S.R., Rudin, C.M., Maitra,  a., 
2012. A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of 
Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational 
Resistance to Smoothened Antagonists. Mol. Cancer Ther. 11, 165–173. 
doi:10.1158/1535-7163.MCT-11-0341 
Cirstea, D., Hideshima, T., Rodig, S., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., 
Perrone, G., Gorgun, G., Patel, K., Desai, N., Sportelli, P., Kapoor, S., Vali, 
S., Mukherjee, S., Munshi, N.C., Anderson, K.C., Raje, N., 2010. Dual 
Inhibition of Akt / Mammalian Target of Rapamycin Pathway by 
Nanoparticle Albumin-Bound – Rapamycin and Perifosine Induces 




Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., Ruiz i Altaba, A., 
2007. HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, 
Cancer Stem Cell Self-Renewal, and Tumorigenicity. Curr. Biol. 17, 165–
172. doi:10.1016/j.cub.2006.11.033 
Clevers, H., 2011. The cancer stem cell: premises, promises and challenges. Nat. 
Med. 17, 313–319. doi:10.1038/nm.2304 
Coni, S., Infante, P., Gulino, A., 2013. Control of stem cells and cancer stem 
cells by Hedgehog signaling: Pharmacologic clues from pathway dissection. 
Biochem. Pharmacol. 85, 623–628. doi:10.1016/j.bcp.2012.11.001 
Cosse, J.-P., Michiels, C., 2008. Tumour hypoxia affects the responsiveness of 
cancer cells to chemotherapy and promotes cancer progression. Anticancer. 
Agents Med. Chem. 8, 790–7. doi:10.2174/187152008785914798 
Cox, T.R., Erler, J.T., 2011. Remodeling and homeostasis of the extracellular 
matrix: implications for fibrotic diseases and cancer. Dis. Model. Mech. 4, 
165–78. doi:10.1242/dmm.004077 
Cui, F.-Y., Song, X.-R., Li, Z.-Y., Li, S.-Z., Mu, B., Mao, Y.-Q., Wei, Y.-Q., 
Yang, L., 2010. The pigment epithelial-derived factor gene loaded in PLGA 
nanoparticles for therapy of colon carcinoma. Oncol. Rep. 24, 661–668. 
doi:10.3892/or_00000905 
Dass, C.R., Contreras, K.G., Dunstan, D.E., Choong, P.F.M., 2007. Chitosan 
microparticles encapsulating PEDF plasmid demonstrate efficacy in an 




Dean, M., Fojo, T., Bates, S., 2005. Tumour stem cells and drug resistance. Nat. 
Rev. Cancer 5, 275–284. doi:10.1038/nrc1590 
Dolcet, X., Llobet, D., Pallares, J., Matias-Guiu, X., 2005. NF-kB in 
development and progression of human cancer. Virchows Arch. 446, 475–
482. doi:10.1007/s00428-005-1264-9 
Dranoff, G., 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. 
Rev. Cancer 4, 11–22. doi:10.1038/nrc1252 
Ek, E.T.H., Dass, C.R., Choong, P.F.M., 2006. PEDF: a potential molecular 
therapeutic target with multiple anti-cancer activities. Trends Mol. Med. 12, 
497–502. doi:10.1016/j.molmed.2006.08.009 
Ek, E.T.H., Dass, C.R., Contreras, K.G., Choong, P.F.M., 2007. Pigment 
epithelium-derived factor overexpression inhibits orthotopic osteosarcoma 
growth , angiogenesis and metastasis. Cancer Gene Ther. 14, 616–626. 
doi:10.1038/sj.cgt.7701044 
Eliyahu, H., Makovitzki, A., Azzam, T., Zlotkin, A., Joseph, A., Gazit, D., 
Barenholz, Y., Domb, A.J., 2005. Novel dextran-spermine conjugates as 
transfecting agents: comparing water-soluble and micellar polymers. Gene 
Ther. 12, 494–503. doi:10.1038/sj.gt.3302395 
Eloy, J.O., Petrilli, R., Topan, J.F., Antonio, H.M.R., Barcellos, J.P.A., Chesca, 
D.L., Serafini, L.N., Tiezzi, D.G., Lee, R.J., Marchetti, J.M., 2016. Co-
loaded paclitaxel/rapamycin liposomes: Development, characterization and 
in vitro and in vivo evaluation for breast cancer therapy. Colloids Surfaces 
B Biointerfaces 141, 74–82. doi:10.1016/j.colsurfb.2016.01.032 
57 
 
Farrar, W.L., 2009. Cancer Stem Cells. N. Engl. J. Med. 355, 1–191. 
doi:10.5858/arpa.2012-0494-RA 
Geiger, B., Bershadsky, A., Pankov, R., Yamada, K.M., 2001. Transmembrane 
crosstalk between the extracellular matrix-cytoskeleton crosstalk. Nat. Rev. 
Mol. Cell Biol. 2, 793–805. doi:10.1038/35099066 
Giri, S., Karakoti, A., Graham, R.P., Maguire, J.L., Reilly, C.M., Seal, S., Rattan, 
R., Shridhar, V., 2013. Nanoceria: A Rare-Earth Nanoparticle as a Novel 
Anti-Angiogenic Therapeutic Agent in Ovarian Cancer. PLoS One 8. 
doi:10.1371/journal.pone.0054578 
Goffin, J.R., Anderson, I.C., Supko, J.G., Eder, J.P., Shapiro, G.I., Lynch, T.J., 
Shipp, M., Johnson, B.E., Skarin, A.T., 2005. Clinical Phase I Trial of the 
Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin 
and Paclitaxel in Patients with Advanced Non Small Cell Lung Cancer. Clin. 
Cancer Res. 11, 3417–3424. doi:10.1158/1078-0432.CCR-04-2144 
Goldberg, M.S., 2015. Immunoengineering: How nanotechnology can enhance 
cancer immunotherapy. Cell 161, 201–204. doi:10.1016/j.cell.2015.03.037 
Gonzalez-Gomez, P., Anselmo, N.P., Mira, H., 2014. BMPs as therapeutic 
targets and biomarkers in astrocytic glioma. Biomed Res. Int. 2014, 1–8. 
doi:10.1155/2014/549742 
González-Gómez, P., Crecente-Campo, J., Zahonero, C., Fuente, M. de la, 
Hernández-Laín, A., Mira, H., Sánchez-Gómez, P., Garcia-Fuentes, M., de 
la Fuente, M., Pilar González-Gómez, Jose Crecente-Campo, Cristina 
Zahonero, Maria de la Fuente, Aurelio Hernández-Laín, Helena Mira, Pilar 
58 
 
Sánchez-Gómez, M.G.-F., 2015. Controlled release microspheres loaded 
with BMP7 suppress primary tumors from human glioblastoma. Oncotarget 
6, 10950–10963. doi:10.18632/oncotarget.3459 
Goodman, T.T., Olive, P.L., Pun, S.H., 2007. Increased nanoparticle penetration 
in collagenase-treated multicellular spheroids. Int. J. Nanomedicine 2, 265–
274. 
Greaves, M., Maley, C.C., 2012. Clonal evolution in cancer. Nature 481, 306–
13. doi:10.1038/nature10762 
Grivennikov, S.I., Greten, F.R., Karin, M., 2010. Immunity , Inflammation , and 
Cancer. Cell 140, 883–899. doi:10.1016/j.cell.2010.01.025 
Guo, L., Peng, Y., Yao, J., Sui, L., Gu, A., Wang, J., 2010. Anticancer Activity 
and Molecular Mechanism of Resveratrol–Bovine Serum Albumin 
Nanoparticles on Subcutaneously Implanted Human Primary Ovarian 
Carcinoma Cells in Nude Mice. Cancer Biother. Radiopharm. 25, 471–477. 
doi:10.1089/cbr.2009.0724 
Gurunathan, S., Lee, K.-J., Kalishwaralal, K., Sheikpranbabu, S., Vaidyanathan, 
R., Eom, S.H., 2009. Antiangiogenic properties of silver nanoparticles. 
Biomaterials 30, 6341–6350. doi:10.1016/j.biomaterials.2009.08.008 
Hambardzumyan, D., Becher, O.J., Rosenblum, M.K., Pandolfi, P.P., Manova-
todorova, K., Holland, E.C., 2008. Perivascular niche following radiation in 
medulloblastoma in vivo PI3K pathway regulates survival of cancer stem 
cells residing in the perivascular niche following radiation in 




Hamdy, S., Molavi, O., Ma, Z., Haddadi, A., Alshamsan, A., Gobti, Z., Elhasi, 
S., Samuel, J., Lavasanifar, A., 2008. Co-delivery of cancer-associated 
antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces 
potent CD8 + T cell-mediated anti-tumor immunity. Vaccine 26, 5046–
5057. doi:10.1016/j.vaccine.2008.07.035 
He, X.-W., Liu, T., Xiao, Y., Feng, Y.-L., Cheng, D.-J., Tingting, G., Zhang, L., 
Zhang, Y., Chen, Y.-X., 2009. Vascular endothelial growth factor-C siRNA 
delivered via calcium carbonate nanoparticle effectively inhibits 
lymphangiogenesis and growth of colorectal cancer in vivo. Cancer Biother. 
Radiopharm. 24, 249–59. doi:10.1089/cbr.2008.0515 
He, X., Liu, T., Chen, Y., Cheng, D., Li, X., Xiao, Y., Feng, Y., 2008. Calcium 
carbonate nanoparticle delivering vascular endothelial growth factor-C 
siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer 
in vivo. Cancer Gene Ther. 15, 193–202. doi:10.1038/sj.cgt.7701122 
Heddleston, J.M., Li, Z., McLendon, R.E., Hjelmeland, A.B., Rich, J.N., 2009. 
The hypoxic microenvironment maintains glioblastoma stem cells and 
promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 
8, 3274–3284. doi:10.4161/cc.8.20.9701 
Helbig, G., Christopherson, K.W., Bhat-nakshatri, P., Kumar, S., Kishimoto, H., 
Miller, K.D., Broxmeyer, H.E., Nakshatri, H., 2003. NF- kB Promotes 
Breast Cancer Cell Migration and Metastasis by Inducing the Expression of 




Hermann, P.C., Bhaskar, S., Cioffi, M., Heeschen, C., 2010. Cancer stem cells 
in solid tumors. Semin. Cancer Biol. 20, 77–84. 
doi:10.1016/j.semcancer.2010.03.004 
Hirakawa, S., 2009. From tumor lymphangiogenesis to lymphvascular niche. 
Cancer Sci. 100, 983–989. doi:10.1111/j.1349-7006.2009.01142.x 
Hoesel, B., Schmid, J. a, 2013. The complexity of NF-κB signaling in 
inflammation and cancer. Mol. Cancer 12, 86. 
doi:10.1101/cshperspect.a000141 
Hori, Y., Stern, P.J., Hynes, R.O., Irvine, D.J., 2009. Engulfing tumors with 
synthetic extracellular matrices for cancer immunotherapy. Biomaterials 30, 
6757–6767. doi:10.1016/j.biomaterials.2009.08.037 
Huang, Z., Yang, Y., Jiang, Y., Shao, J., Sun, X., Chen, J., Dong, L., Zhang, J., 
2013. Anti-tumor immune responses of tumor-associated macrophages via 
toll-like receptor 4 triggered by cationic polymers. Biomaterials 34, 746–
755. doi:10.1016/j.biomaterials.2012.09.062 
Hwang, S.R., Lim, S.J., Park, J.S., Kim, C.K., 2004. Phospholipid-based 
microemulsion formulation of all-trans-retinoic acid for parenteral 
administration. Int. J. Pharm. 276, 175–183. 
doi:10.1016/j.ijpharm.2004.02.025 
Iozzo, R. V., Sanderson, R.D., 2011. Proteoglycans in cancer biology, tumour 




Jain, R.K., 2005. Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science (80-. ). 307, 58–62. 
doi:10.1126/science.1104819 
Jeong, Y.-I., Kang, M.-K., Sun, H.-S., Kang, S.-S., Kim, H.-W., Moon, K.-S., 
Lee, K.-J., Kim, S.-H., Jung, S., 2004. All-trans-retinoic acid release from 
core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene 
glycol) diblock copolymer. Int. J. Pharm. 273, 95–107. 
doi:10.1016/j.ijpharm.2003.12.012 
Kahn, M., 2014. Can we safely target the WNT pathway? Nat. Rev. Drug Discov. 
13, 513–32. doi:10.1038/nrd4233 
Kaiser, B.J., 2015. Researchers are betting that a round of clinical trials will 
prove a controversial cancer theory and deliver new treatments. Science (80-
. ). 347, 226–229. doi:10.1126/science.347.6219.226 
Kakinuma, T., Hwang, S.T., 2006. Chemokines, chemokine receptors, and 
cancer metastasis. J. Leukoc. Biol. 79, 639–51. doi:10.1189/jlb.1105633 
Kallioniemi, A., 2012. Bone morphogenetic protein 4-a fascinating regulator of 
cancer cell behavior. Cancer Genet. 205, 267–277. 
doi:10.1016/j.cancergen.2012.05.009 
Kalluri, R., Zeisberg, M., 2006. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392–
401. doi:10.1038/nrc1877 
Kanapathipillai, M., Brock, A., Ingber, D.E., 2014. Nanoparticle targeting of 
anti-cancer drugs that alter intracellular signaling or influence the tumor 




Kanapathipillai, M., Mammoto, A., Mammoto, T., Kang, J.H., Jiang, E., Ghosh, 
K., Korin, N., Gibbs, A., Mannix, R., Ingber, D.E., 2012. Inhibition of 
Mammary Tumor Growth Using Lysyl Oxidase- Targeting Nanoparticles to 
Modify Extracellular Matrix. Nano Lett. 12, 3213–3217. doi:DOI: 
10.1021/nl301206p 
Kang, H., Jin, S., Myung, C., Hwang, S., Park, S., Kang, H., Jin, S., Myung, C., 
Hwang, S., Park, J., 2009. Delivery of interleukin-18 gene to lung cancer 
cells using cationic emulsion. J. Drug Target. 17, 19–28. 
doi:10.1080/10611860802438710 
Kang, H., Watkins, G., Douglas-Jones, A., Mansel, R.E., Jiang, W.G., 2005. The 
elevated level of CXCR4 is correlated with nodal metastasis of human breast 
cancer. Breast 14, 360–367. doi:10.1016/j.breast.2004.12.007 
Karthikeyan, S., Prasad, R.R., Ganamani, A., Balamurugan, E., 2013. Anticancer 
activity of resveratrol-loaded gelatin nanoparticles on NCI-H460 non-small 
cell lung cancer cells. Biomed. Prev. Nutr. 3, 64–73. 
doi:10.1016/j.bionut.2012.10.009 
Kawamata, H., Tachibana, M., Fujimori, T., Imai, Y., 2006. Differentiation-
inducing therapy for solid tumors. Curr. Pharm. Des. 12, 379–385. 
doi:10.2174/138161206775201947 
Keith, B., Simon, M.C., 2007. Hypoxia-Inducible Factors, Stem Cells, and 
Cancer. Cell 129, 465–472. doi:10.1016/j.cell.2007.04.019 
Kim, S.H., Turnbull, J., Guimond, S., 2011. Extracellular matrix and cell 
63 
 
signalling: The dynamic cooperation of integrin, proteoglycan and growth 
factor receptor. J. Endocrinol. 209, 139–151. doi:10.1530/JOE-10-0377 
Kobayashi, H., Lin, P.C., 2006. Nanotechnology for antiangiogenic cancer 
therapy. Nanomedicine (Lond). 1, 17–22. doi:10.2217/17435889.1.1.17 
Kosmidou, I., Xagorari, A., Roussos, C., Papapetropoulos, A., 2001. Reactive 
oxygen species stimulate VEGF production from C2C12 skeletal myotubes 
through a PI3K/Akt pathway. Am. J. lung cell Mol. Physiol. 280, L585–
L592. 
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., Fisher, P.B., 2001. 
Differentiation therapy of human cancer: basic science and clinical 
applications. Pharmacol. Ther. 90, 105–156. doi:10.1016/S0163-
7258(01)00132-2 
Li, L., Yang, J., Wang, W.W., Yao, Y.C., Fang, S.H., Dai, Z.Y., Hong, H.H., 
Yang, X., Shuai, X.T., Gao, G.Q., 2012. Pigment epithelium-derived factor 
gene loaded in cRGD-PEG-PEI suppresses colorectal cancer growth by 
targeting endothelial cells. Int. J. Pharm. 438, 1–10. 
doi:10.1016/j.ijpharm.2012.08.043 
Li, R.J., Ying, X., Zhang, Y., Ju, R.J., Wang, X.X., Yao, H.J., Men, Y., Tian, 
W., Yu, Y., Zhang, L., Huang, R.J., Lu, W.L., 2011. All-trans retinoic acid 
stealth liposomes prevent the relapse of breast cancer arising from the cancer 
stem cells. J. Control. Release 149, 281–291. 
doi:10.1016/j.jconrel.2010.10.019 
Li, T., Wang, G.D., Tan, Y.Z., Wang, H.J., 2014. Inhibition of 
64 
 
lymphangiogenesis of endothelial progenitor cells with VEGFR-3 siRNA 
delivered with PEI-alginate nanoparticles. Int. J. Biol. Sci. 10, 160–170. 
doi:10.7150/ijbs.6719 
Li, X., Lu, X., Xu, H., Zhu, Z., Yin, H., Qian, X., Li, R., Jiang, X., Liu, B., 2012. 
Paclitaxel/tetrandrine coloaded nanoparticles effectively promote the 
apoptosis of gastric cancer cells based on “oxidation therapy.” Mol. Pharm. 
9, 222–229. doi:10.1021/mp2002736 
Liang, Z., Wu, T., Lou, H., Umbreit, J., Shim, H., 2004. Inhibition of Breast 
Cancer Metastasis by Selective Synthetic Polypeptide against CXCR4 
Inhibition of Breast Cancer Metastasis by Selective Synthetic Polypeptide 
against CXCR4. Cancer Res. 64, 4302–4308. doi:10.1158/0008-5472.CAN-
03-3958 
Lim, K.J., Bisht, S., Bar, E.E., Maitra, A., Eberhart, C.G., 2011. A polymeric 
nanoparticle formulation of curcumin inhibits growth, clonogenicity and 
stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 11, 464–
473. doi:10.4161/cbt.11.5.14410 
Lim, S., Lee, M., Kim, C., 2004. Altered chemical and biological activities of 
all- trans retinoic acid incorporated in solid lipid nanoparticle powders. J. 
Control. Release 100, 53–61. doi:10.1016/j.jconrel.2004.07.032 
Lisignoli, G., Cristino, S., Piacentini, A., Cavallo, C., Caplan, A.I., Facchini, A., 
2006. Hyaluronan-Based Polymer Scaffold Modulates the Expression of 
Inflammatory and Degradative Factors in Mesenchymal Stem Cells: 




Liu, J.T., Chen, Y.L., Chen, W.C., Chen, H.Y., Lin, Y.W., Wang, S.H., Man, 
K.M., Wan, H.M., Yin, W.H., Liu, P.L., Chen, Y.H., 2012. Role of pigment 
epithelium-derived factor in stem/progenitor cell-associated 
neovascularization. J. Biomed. Biotechnol. 1–10. doi:10.1155/2012/871272 
Liu, L., Sakaguchi, Æ.T., Kanda, Æ.T., 2003. Delivery of interleukin-12 in 
gelatin hydrogels effectively suppresses development of transplanted 
colonal carcinoma in mice. Cancer Chemother Pharmacol 51, 53–57. 
doi:10.1007/s00280-002-0547-y 
Liu, P., Brown, S., Goktug, T., Channathodiyil, P., Kannappan, V., Hugnot, J., 
Guichet, P., Bian, X., Armesilla, A.L., Darling, J.L., Wang, W., 2012. 
Cytotoxic effect of disulfiram / copper on human glioblastoma cell lines and 
ALDH-positive cancer-stem-like cells. Br. J. Cancer 107, 1488–1497. 
doi:10.1038/bjc.2012.442 
Liu, P., Wang, Z., Brown, S., Kannappan, V., Erebi, P., Jiang, W., Irache, J.M., 
Tang, J.Z., Britland, S., Armesilla, A.L., Darling, J.L., Tang, X., Wang, W., 
2014. Liposome encapsulated Disulfiram inhibits NFκB pathway and 
targets breast cancer stem cells in vitro and in vivo. Oncotarget 5, 7471–
7485. doi:10.18632/oncotarget.2166 
Liu, S., Dontu, G., Wicha, M.S., 2005. Mammary stem cells, self-renewal 
pathways, and carcinogenesis. Breast cancer Res. 7, 86–95. 
doi:10.1186/bcr1021 
Liu, X.Q., Xiong, M.H., Shu, X.T., Tang, R.Z., Wang, J., 2012. Therapeutic 
66 
 
delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles 
inhibits hypoxic tumor growth. Mol. Pharm. 9, 2863–2874. 
doi:10.1021/mp300193f 
Lu, H., Li, Y., Shu, M., Tang, J., Huang, Y., Zhou, Y., Liang, Y., Yan, G., 2009. 
Hypoxia-inducible factor-1alfa blocks differentiation of malignant gliomas. 
FEBS J. 276, 7291–7304. doi:10.1111/j.1742-4658.2009.07441.x 
Lu, J., Zhao, W., He, W., Wei, W., 2012. Hedgehog signaling pathway mediates 
invasion and metastasis of hepatocellular carcinoma via ERK pathway. Acta 
Pharmacol. Sin. 33, 691–700. doi:10.1038/aps.2012.24 
Lu, P., Weaver, V.M., Werb, Z., 2012. The extracellular matrix: A dynamic 
niche in cancer progression. J. Cell Biol. 196, 395–406. 
doi:10.1083/jcb.201102147 
Lu, X.-Y., Hu, S., Jin, Y., Qiu, L.-Y., 2012. Application of liposome 
encapsulation technique to improve anti-carcinoma effect of resveratrol. 
Drug Dev. Ind. Pharm. 38, 314–22. doi:10.3109/03639045.2011.602410 
Maheshwari, A., Mahato, R.I., Mcgregor, J., Han, S., Samlowski, W.E., Park, J., 
Kim, S.W., 2000. Soluble Biodegradable Polymer-Based Cytokine Gene 
Delivery for Cancer Treatment. Mol. Ther. 2, 121–130. 
doi:10.1006/mthe.2000.0105 
Marotta, L.L.C., Polyak, K., 2009. Cancer stem cells: a model in the making. 
Curr. Opin. Genet. Dev. 19, 44–50. doi:10.1016/j.gde.2008.12.003 
Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, 
B., Tian, Y.M., Lanahan, A.A., Pollard, P., Ruiz de Almodovar, C., De 
67 
 
Smet, F., Vinckier, S., Aragon??s, J., Debackere, K., Luttun, A., Wyns, S., 
Jordan, B., Pisacane, A., Gallez, B., Lampugnani, M.G., Dejana, E., Simons, 
M., Ratcliffe, P., Maxwell, P., Carmeliet, P., 2009. Heterozygous 
Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis 
via Endothelial Normalization. Cell 136, 839–851. 
doi:10.1016/j.cell.2009.01.020 
Mehta, K., Sadeghi, T., MacQueen, T., Lopez-Berestein, G., 1994. Liposome 
encapsulation circumvents the hepatic clearance mechanism of all-trans-
retinoic acid. Leuk. Res. 8, 587–596. doi:10.1016/0145-2126(94)90040-X 
Merchant, A.A., Matsui, W., 2010. Targeting Hedgehog - A cancer stem cell 
pathway. Clin. Cancer Res. 16, 3130–3140. doi:10.1158/1078-0432.CCR-
09-2846 
Mishra, G.P., Nguyen, D., Alani, A.W.G., 2013. Inhibitory effect of paclitaxel 
and rapamycin individual and dual drug-loaded polymeric micelles in the 
angiogenic cascade. Mol. Pharm. 10, 2071–2078. doi:10.1021/mp400122m 
Misra, A.C., Luker, K.E., Durmaz, H., Luker, G.D., Lahann, J., 2015. CXCR4-
Targeted Nanocarriers for Triple Negative Breast Cancers. 
Biomacromolecules 16, 2412–2417. doi:10.1021/acs.biomac.5b00653 
Mohyeldin, A., Garzón-Muvdi, T., Quiñones-Hinojosa, A., 2010. Oxygen in 
stem cell biology: A critical component of the stem cell niche. Cell Stem 
Cell 7, 150–161. doi:10.1016/j.stem.2010.07.007 
Morral-Ruiz, G., Melgar-Lesmes, P., Solans, C., Garcia-Celma, M.J., 2013. 
Multifunctional polyurethane-urea nanoparticles to target and arrest 
68 
 
inflamed vascular environment: A potential tool for cancer therapy and 
diagnosis. J. Control. Release 171, 163–171. 
doi:10.1016/j.jconrel.2013.06.027 
Mukherjee, P., Bhattacharya, R., Wang, P., Wang, L., Basu, S., Nagy, J. a, Atala, 
A., Mukhopadhyay, D., Soker, S., 2005. Antiangiogenic properties of gold 
nanoparticles. Clin. Cancer Res. 11, 3530–3534. doi:10.1158/1078-
0432.CCR-04-2482 
Nayab, S.N., Jones, F.H., Olsen, I., 2007. Modulation of the human bone cell 
cycle by calcium ion-implantation of titanium. Biomaterials 28, 38–44. 
doi:10.1016/j.biomaterials.2006.08.032 
Netti, P.A., Berk, D.A., Swartz, M.A., Grodzinsky, A.J., Jain, R.K., 2000. Role 
of extracellular matrix assembly in interstitial transport in solid tumors. 
Cancer Res. 60, 2497–2503. 
Noy, R., Pollard, J.W., 2014. Tumor-Associated Macrophages: From 
Mechanisms to Therapy. Immunity 41, 49–61. 
doi:10.1016/j.immuni.2014.06.010 
Oskarsson, T., 2013. Extracellular matrix components in breast cancer 
progression and metastasis. The Breast 22, S66–S72. 
doi:10.1016/j.breast.2013.07.012 
Padera, T.P., Stoll, B.R., Tooredman, J.B., Capen, D., di Tomaso, E., Jain, R.K., 
2004. Pathology: cancer cells compress intratumour vessels. Nature 427, 
695. doi:10.1038/427695a 
Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., Miele, 
69 
 
L., 2010. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 16, 
3141–3152. doi:10.1158/1078-0432.CCR-09-2823 
Park, J., Wrzesinski, S.H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, 
S.M., Demento, S.L., Agawu, A., Limon, P.L., Ferrandino, A.F., Gonzalez, 
D., Habermann, A., Flavell, R.A., Fahmy, T.M., 2012. Combination 
delivery of TGF- inhibitor and IL-2 by nanoscale liposomal polymeric gels 
enhances tumour immunotherapy. Nat. Mater. 11, 895–905. 
doi:10.1038/nmat3355 
Pattabiraman, D.R., Weinberg, R.A., 2014. Tackling the cancer stem cells - what 
challenges do they pose? Nat Rev Drug Discov 13, 497–512. 
doi:10.1038/nrd4253 
Persano, L., Rampazzo, E., Basso, G., Viola, G., 2013. Glioblastoma cancer stem 
cells: role of the microenvironment and therapeutic targeting. Biochem 
Pharmacol 85, 612–622. doi:10.1016/j.bcp.2012.10.001 
Piao, L., Zhang, M., Datta, J., Xie, X., Su, T., Li, H., Teknos, T.N., Pan, Q., 2012. 
Lipid-based Nanoparticle Delivery of Pre-miR-107 Inhibits the 
Tumorigenicity of Head and Neck Squamous Cell Carcinoma. Mol. Ther. 
20, 1261–1269. doi:10.1038/mt.2012.67 
Prabhakaran, M.P., Venugopal, J.R., Ramakrishna, S., 2009. Mesenchymal stem 
cell differentiation to neuronal cells on electrospun nanofibrous substrates 
for nerve tissue engineering. Biomaterials 30, 4996–5003. 
doi:10.1016/j.biomaterials.2009.05.057 
Quante, M., Tu, S.P., Tomita, H., Gonda, T., Wang, S.S.W., Takashi, S., Baik, 
70 
 
G.H., Shibata, W., Diprete, B., Betz, K.S., Friedman, R., Varro, A., Tycko, 
B., Wang, T.C., 2011. Bone Marrow-Derived Myofibroblasts Contribute to 
the Mesenchymal Stem Cell Niche and Promote Tumor Growth. Cancer 
Cell 19, 257–272. doi:10.1016/j.ccr.2011.01.020 
Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. a, Borgel, S.D., 
Carter, J.P., Gehrs, B., Raffeld, M., Kinders, R.J., Parchment, R., Anver, 
M.R., Shoemaker, R.H., Melillo, G., 2009. Increased antitumor activity of 
bevacizumab in combination with hypoxia inducible factor-1 inhibition. 
Mol. Cancer Ther. 8, 1867–1877. doi:10.1158/1535-7163.MCT-09-0274 
Reguera-Nuñez, E., Roca, C., Hardy, E., de la Fuente, M., Csaba, N., Garcia-
Fuentes, M., 2014. Implantable controlled release devices for BMP-7 
delivery and suppression of glioblastoma initiating cells. Biomaterials 35, 
2859–2867. doi:10.1016/j.biomaterials.2013.12.001 
Reya, T., Clevers, H., 2005. Wnt signalling in stem cells and cancer. Nature 434, 
843–50. doi:10.1038/nature03319 
Rintoul, R.C., Sethi, T., 2002. Extracellular matrix regulation of drug resistance 
in small-cell lung cancer. Clin. Sci. (Lond). 102, 417–424. 
doi:10.1080/09553000701570204 
Rosenbaum, E., Zahurak, M., Sinibaldi, V., Carducci, M.A., Pili, R., Laufer, M., 
Deweese, T.L., Eisenberger, M.A., 2005. Marimastat in the Treatment of 
Patients with Biochemically Relapsed Prostate Cancer: A Prospective 




Roy, A., Singh, M.S., Upadhyay, P., Bhaskar, S., 2013. Nanoparticle mediated 
co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression 
and enhanced immune response in the tumor microenvironment of a mouse 
model. Int. J. Pharm. 445, 171–180. doi:10.1016/j.ijpharm.2013.01.045 
Sabel, M.S., Skitzki, J., Stoolman, L., Egilmez, N.K., Mathiowitz, E., Bailey, N., 
Chang, W., Chang, A.E., 2004. Intratumoral IL-12 and TNF-a- Loaded 
Microspheres Lead To Regression of Breast Cancer and Systemic 
Antitumor Immunity. Ann. Surg. Oncol. 11, 147–156. 
doi:10.1245/ASO.2004.03.022 
Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida, 
K., Harashima, H., 2013. RNAi-mediated gene knockdown and anti-
angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-
siRNA system. J. Control. Release 173, 110–118. 
doi:10.1016/j.jconrel.2013.10.003 
Sanna, V., Siddiqui, I.A., Sechi, M., Mukhtar, H., 2013. Resveratrol-loaded 
nanoparticles based on poly(epsiloncaprolactone) and poly(D,L-lactic-co-
glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment. 
Mol. Pharm. 10, 3871–3881. doi:10.1021/mp400342f 
Satchi-Fainaro, R., Mamluk, R., Wang, L., Short, S.M., Nagy, J.A., Feng, D., 
Dvorak, A.M., Dvorak, H.F., Puder, M., Mukhopadhyay, D., Folkman, J., 
2005. Inhibition of vessel permeability by TNP-470 and its polymer 




Satchi-Fainaro, R., Puder, M., Davies, J.W., Tran, H.T., Sampson, D. a, Greene, 
A.K., Corfas, G., Folkman, J., 2004. Targeting angiogenesis with a 
conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255–261. 
doi:10.1038/nm1002 
Schätzlein, A.G., 2006. Delivering cancer stem cell therapies - A role for 
nanomedicines? Eur. J. Cancer 42, 1309–1315. 
doi:10.1016/j.ejca.2006.01.044 
Schneider, R.K., Anraths, J., Kramann, R., Bornemann, J., Bovi, M., Knüchel, 
R., Neuss, S., 2010. The role of biomaterials in the direction of 
mesenchymal stem cell properties and extracellular matrix remodelling in 
dermal tissue engineering. Biomaterials 31, 7948–7959. 
doi:10.1016/j.biomaterials.2010.07.003 
Schultz, G.S., Wysocki, A., 2009. Interactions between extracellular matrix and 
growth factors in wound healing. Wound Repair Regen. 17, 153–162. 
doi:10.1111/j.1524-475X.2009.00466.x 
Seidel, S., Garvalov, B.K., Wirta, V., Stechow, L. Von, Scha, A., Meletis, K., 
Wolter, M., Sommerlad, D., Henze, A., Reifenberger, G., Lundeberg, J., 
Frise, J., Niste, M., 2010. A hypoxic niche regulates glioblastoma stem cells 
through hypoxia inducible factor 2 a. Brain 133, 983–995. 
doi:10.1093/brain/awq042 
Shao, J., Li, X., Lu, X., Jiang, C., Hu, Y., Li, Q., You, Y., Fu, Z., 2009. Enhanced 
growth inhibition effect of Resveratrol incorporated into biodegradable 
nanoparticles against glioma cells is mediated by the induction of 
73 
 
intracellular reactive oxygen species levels. Colloids Surfaces B 
Biointerfaces 72, 40–47. doi:10.1016/j.colsurfb.2009.03.010 
Shimizu, T., Kishida, T., Hasegawa, U., Ueda, Y., Imanishi, J., Yamagishi, H., 
Akiyoshi, K., Otsuji, E., Mazda, O., 2008. Nanogel DDS enables sustained 
release of IL-12 for tumor immunotherapy. Biochem. Biophys. Res. 
Commun. 367, 330–335. doi:10.1016/j.bbrc.2007.12.112 
Singh, A., Settleman, J., 2010. EMT, cancer stem cells and drug resistance: an 
emerging axis of evil in the war on cancer. Oncogene 29, 4741–51. 
doi:10.1038/onc.2010.215 
Skvortsov, S., Debbage, P., Lukas, P., Skvortsova, I., 2015. Crosstalk between 
DNA repair and cancer stem cell (CSC) associated intracellular pathways. 
Semin. Cancer Biol. 31, 36–42. doi:10.1016/j.semcancer.2014.06.002 
Spira, A.I., Carducci, M.A., 2003. Differentiation therapy. Curr. Opin. 
Pharmacol. 3, 338–343. doi:10.1016/S1471-4892(03)00081-X 
Stegemann, J.P., Nerem, R.M., 2003. Phenotype modulation in vascular tissue 
engineering using biochemical and mechanical stimulation. Ann. Biomed. 
Eng. 31, 391–402. doi:10.1114/1.1558031 
Sun, M., Nie, S., Pan, X., Zhang, R., Fan, Z., Wang, S., 2014. Quercetin-
nanostructured lipid carriers : Characteristics and anti-breast cancer 
activities in vitro. Colloids Surfaces B Biointerfaces 113, 15–24. 
doi:10.1016/j.colsurfb.2013.08.032 
Sun, R., Liu, Y., Li, S.Y., Shen, S., Du, X.J., Xu, C.F., Cao, Z.T., Bao, Y., Zhu, 
Y.H., Li, Y.P., Yang, X.Z., Wang, J., 2015. Co-delivery of all-trans-retinoic 
74 
 
acid and doxorubicin for cancer therapy with synergistic inhibition of cancer 
stem cells. Biomaterials 37, 405–414. 
doi:10.1016/j.biomaterials.2014.10.018 
Swartz, M.A., Skobe, M., 2001. Lymphatic function, lymphangiogenesis, and 
cancer metastasis. Microsc. Res. Tech. 55, 92–99. doi:10.1002/jemt.1160 
Takebe, N., Harris, P.J., Warren, R.Q., Ivy, S.P., 2011. Targeting cancer stem 
cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. 
Oncol. 8, 97–106. doi:10.1038/nrclinonc.2010.196 
Takebe, N., Miele, L., Harris, P.J., Jeong, W., Bando, H., Kahn, M., Yang, S.X., 
Ivy, S.P., 2015. Targeting Notch, Hedgehog, and Wnt pathways in cancer 
stem cells: clinical update. Nat. Rev. Clin. Oncol. 12, 445–64. 
doi:10.1038/nrclinonc.2015.61 
Thomas, C.E., Ehrhardt, A., Kay, M.A., 2003. Progress and problems with the 
use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346–358. 
doi:10.1038/nrg1066 
Tian, W., Liu, J., Guo, Y., Shen, Y., Zhou, D., Guo, S., 2015. Self-assembled 
micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and 
resisting multidrug resistant cancer cells†Electronic supplementary 
information (ESI) available: Chemicals and reagents, detailed experimental 
procedures for materials s. J. Mater. Chem. B. Mater. Biol. Med. 3, 1204–
1207. doi:10.1039/c4tb01633e 
Vaupel, P., Mayer, A., 2007. Hypoxia in cancer: Significance and impact on 




Visvader, J.E., Lindeman, G.J., 2008. Cancer stem cells in solid tumours: 
accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755–
68. doi:10.1038/nrc2499 
Wang, J., Wakeman, T.P., Lathia, J.D., Hjelmeland, A.B., Wang, X.F., White, 
R.R., Rich, J.N., Sullenger, B.A., 2010. Notch promotes radioresistance of 
glioma stem cells. Stem Cells 28, 17–28. doi:10.1002/stem.261 
Wang, K., Zhang, T., Liu, L., Wang, X., Wu, P., Chen, Z., Ni, C., Zhang, J., Hu, 
F., Huang, J., 2012. Novel micelle formulation of curcumin for enhancing 
antitumor activity and inhibiting colorectal cancer stem cells. Int. J. 
Nanomedicine 7, 4487–4497. doi:10.2147/IJN.S34702 
Wang, Y., Gao, S., Ye, W.-H., Yoon, H.S., Yang, Y., 2006. Co-delivery of drugs 
and DNA from cationic core–shell nanoparticles self-assembled from a 
biodegradable copolymer. Nat. Mater. 5, 791–796. doi:10.1038/nmat1737 
West, N.R., McCuaig, S., Franchini, F., Powrie, F., 2015. Emerging cytokine 
networks in colorectal cancer. Nat. Rev. Immunol. 15, 615–629. 
doi:10.1038/nri3896 
Wicha, M.S., Liu, S., Dontu, G., 2006. Cancer stem cells: An old idea - A 
paradigm shift. Cancer Res. 66, 1883–1890. doi:10.1158/0008-5472.CAN-
05-3153 
Wilhelm, S., Tavares, A.J., Dai, Q., Ohta, S., Audet, J., Dvorak, H.F., Chan, 
W.C.W., 2016. Analysis of nanoparticle delivery to tumours. Nat. Rev. 
Mater. 1, 16014. doi:10.1038/natrevmats.2016.14 
76 
 
Wong, M., Chiu, G.N.C., 2011. Liposome formulation of co-encapsulated 
vincristine and quercetin enhanced antitumor activity in a trastuzumab-
insensitive breast tumor xenograft model. Nanomedicine Nanotechnology, 
Biol. Med. 7, 834–840. doi:10.1016/j.nano.2011.02.001 
Woo, H.N., Chung, H.K., Ju, E.J., Jung, J., Kang, H.W., Lee, S.W., Seo, M.H., 
Lee, J.S., Lee, J.S., Park, H.J., Song, S.Y., Jeong, S.Y., Choi, E.K., 2012. 
Preclinical evaluation of injectable sirolimus formulated with polymeric 
nanoparticle for cancer therapy. Int. J. Nanomedicine 7, 2197–2208. 
doi:10.2147/IJN.S29480 
Xia, P., Xu, X.-Y., 2015. PI3K/Akt/mTOR signaling pathway in cancer stem 
cells: from basic research to clinical application. Am. J. Cancer Res. 5, 
1602–9. 
Xu, B., Xia, S., Wang, F., Jin, Q., Yu, T., He, L., Chen, Y., Liu, Y., Li, S., Tan, 
X., Ren, K., Yao, S., Zeng, J., Song, X., 2016. Polymeric Nanomedicine for 
Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression. Mol. 
Pharm. 13, 663–676. doi:10.1021/acs.molpharmaceut.5b00922 
Xu, H., Hou, Z., Zhang, H., Kong, H., Li, X., Wang, H., Xie, W., 2013. An 
efficient trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-
poly(Epsilon-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced 
apoptotic induction of lung cancer cells and inhibition of its migration and 
invasion. Int. J. Nanomedicine 9, 231–242. doi:10.2147/IJN.S55541 
Xu, Q., Guo, L., Gu, X., Zhang, B., Hu, X., Zhang, J., Chen, J., Wang, Y., Chen, 
C., Gao, B., Kuang, Y., Wang, S., 2012. Prevention of colorectal cancer 
77 
 
liver metastasis by exploiting liver immunity via chitosan-TPP / 
nanoparticles formulated with IL-12. Biomaterials 33, 3909–3918. 
doi:10.1016/j.biomaterials.2012.02.014 
Xu, Y., Chenna, V., Hu, C., Sun, H.X., Khan, M., Bai, H., Yang, X.R., Zhu, Q.F., 
Sun, Y.F., Maitra, A., Fan, J., Anders, R.A., 2012. Polymeric nanoparticle-
encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits 
systemic metastases in an orthotopic model of human hepatocellular 
carcinoma. Clin. Cancer Res. 18, 1291–1302. doi:10.1158/1078-0432.CCR-
11-0950 
Yu, B., Tai, H.C., Xue, W., Lee, L.J., Lee, R.J., 2010. Receptor-targeted 
nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 27, 286–
98. doi:10.3109/09687688.2010.521200 
Yu, Z., Pestell, T.G., Lisanti, M.P., Pestell, R.G., 2012. Cancer stem cells. Int. J. 
Biochem. Cell Biol. 44, 2144–2151. doi:10.1016/j.biocel.2012.08.022 
Yuan, Z., Chen, L., Fan, L., Tang, M., Yang, G., Yang, H., Du, X., Wang, G., 
Yao, W., Zhao, Q., Wang, R., Diao, P., Zhang, W., 2006. Liposomal 
Quercetin Efficiently Suppresses Growth of Solid T umors in Murine 
Models. Clin. cancer Res. 12, 3193–3200. doi:10.1158/1078-0432.CCR-05-
2365 
Yücel, Ç., Deǧim, Z., Yilmaz, Ş., 2013. Nanoparticle and liposome formulations 
of doxycycline: Transport properties through Caco-2 cell line and effects on 




Zha, J., Chen, F., Dong, H., Shi, P., Yao, Y., Zhang, Y., Li, R., Wang, S., Li, P., 
Wang, W., Xu, B., 2014. Disulfiram targeting lymphoid malignant cell lines 
via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. J. 
Transl. Med. 12, 163. doi:10.1186/1479-5876-12-163 
Zhang, Z., Tongchusak, S., Mizukami, Y., Joong, Y., Ioji, T., 2011. Induction of 
anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated 
antigen delivery. Biomaterials 32, 3666–3678. 
doi:10.1016/j.biomaterials.2011.01.067 
Zhao, C., Chen, A., Jamieson, C.H., Fereshteh, M., Abrahamsson, A., Blum, J., 
Kwon, H.Y., Kim, J., Chute, J.P., Rizzieri, D., Munchhof, M., VanArsdale, 
T., Beachy, P.A., Reya, T., 2009. Hedgehog signalling is essential for 





Supporting Information  
Table S1: Overview of the drugs in clinical trials against CSCs and/or their niche. Only trials from 







Condition Mechanism of action Number 







Non-squamous non-small-cell lung cancer 
 




























Axitinib Phase III Clear cell renal carcinoma VEGFR inhibitor NCT 01599754 
Aflibercept Phase III Colorectal carcinoma VEGFR inhibitor NCT 01661270 
NCT 01571284 
NCT 01670721 
Ramucirumab Phase III Hepatocellular carcinoma 
Gastric and esophageal adenocarcinoma 
Non-small cell lung cancer 
Urothelial carcinoma 




























Non-small-cell lung cancer 
 
 





















































Advanced pulmonary adenocarcinoma 
 
Non-small cell lung cancer  
 
 































Non-squamous non-small cell lung cancer 
Lung neoplasms 
Thoracic neoplasm 














Sunitinib Phase III  
 
Phase IV 
Renal cell carcinoma 
 
Renal cell carcinoma 
Pancreatic neuroendocrine tumor 






Nintedanib Phase III Non-small-cell lung carcinoma 
Colorectal carcinoma 




















Renal cell carcinoma  
 
Leukemia cutis and myeloid sarcoma 
Hepatocellular carcinoma 
Acute myeloid leukemia 
Renal carcinoma 
 















Pazopanib Phase III 
 
Phase IV 
Renal Cell Carcinoma 
Sarcoma 
Renal Cell Carcinoma 





Motesanib Phase III Non-small cell lung VEGFR and PDGFR 
inhibitor 
NCT 02629848 
Masitinib Phase III 
 
Gastro-intestinal stromal tumour 
Colorectal cancer 
VEGFR and  PDGFR 
inhibitor 
NCT 02009423 
 NCT 02605044 






































































Non squamous non-small-cell lung cancer 


















































EGFR inhibitor NCT 02714010 
NCT 01719536 
NCT 02448797 














Afatinib Phase III Non-small-cell lung carcinoma EGFR inhibitor NCT 01121393 
NCT 00949650 





































NCT 01309126   



























Oropharyngeal Squamous Cell Carcinoma 
Nasopharyngeal Carcinoma 
Colorectal cancer  
 




















Advanced neuroendocrine tumors 





































Nimorazole Phase III Head and neck carcinoma 
 
Inhibit glycolysis and the 
repair of radiation-induced 
cellular potentially lethal 














Acute myeloid leukemia 
 





Acute promyelocytic leukemia 
Expression of genes 














Sulindac Phase III Colorectal adenocarcinoma Inmunomodulador NCT 01349881 
Imiquimod Phase III Nodular basal cell carcinoma 
Intraepithelial neoplasia 
Hedgehog pathway 
inhibitor and 
immunostimulator 
NCT 02242929 
NCT 02329171 
NCT 01283763 
NCT 01861535 
NCT 02059499 
